Stockwinners Market Radar for April 12, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Cathie Wood's ARK Investment bought 50.9K shares of Stratasys today

20:17 EDT Cathie Wood's ARK Investment bought 76.3K shares of Invitae today

18:09 EDT PowerSchool and Ellucian expand partnership - Ellucian announced it is expanding its partnership with PowerSchool. Ellucian and PowerSchool will collaborate with the shared goal to better support career and education pathways for students from kindergarten through college. Ellucian and PowerSchool will collaborate to improve upon how their solutions work together, allowing for a deeper understanding of K-12 student outcomes and how they can affect college and career pathways. In addition, PowerSchool is integrating its PeopleAdmin higher education talent management, faculty management and interoperability products with Ellucian's Experience platform.

18:01 EDT International Game signs broad patent cross-licensing pact with Aristocrat - International Game Technology PLC announced that it has signed a broad patent cross-licensing agreement with Aristocrat Leisure Limited that includes valuable patents related to game features and remote game server technologies. Under the agreement, IGT will be able to offer licenses to the companies' combined game feature and RGS patent portfolios to the global gaming industry. Financial terms of the agreement have not been disclosed. "This agreement extends and expands the previous patent cross-license between IGT and Aristocrat. This combination of two of the gaming industry's most valuable game features and RGS patent portfolios can help propel the evolution of gaming with compelling content and advanced game mechanics," said Renato Ascoli, IGT CEO Global Gaming. "We look forward to providing the entire gaming industry with the opportunity to license IGT and Aristocrat patents, particularly the compelling content resulting from our combined RGS portfolios, in the spirit of competition and innovation."

17:35 EDT Codorus Valley Bancorp to appoint three new directors, implement initiatives - Codorus Valley Bancorp announced it is implementing a series of initiatives designed to enhance the corporation's corporate governance practices, further analyze credit risk policies and practices, and ensure continued alignment with shareholders. These initiatives follow engagement and input from shareholders, including Driver Management and its affiliates, which together own 6.7% of Codorus Valley's outstanding common stock. The corporation will appoint three new directors to its board of directors. The first new director, John Kiernan was appointed by the board at its April 12 meeting. Kiernan was selected from Driver's proposed nominees previously submitted for consideration. The second new director will be chosen solely by the board, and will be appointed no later than the end of Q2. The board and Driver together will identify a third new director with public company board experience from the banking sector. The third new director also will be appointed no later than Q2. Upon completion of these additions, the size of the board will not exceed eleven directors. In addition, the board's compensation committee will undertake a comprehensive study regarding executive compensation initiatives proposed by Driver. The corporation will publicize the results of this compensation study in the ordinary course of business once such results are implemented. The compensation committee will also evaluate stock ownership guidelines for directors of the Corporation. Last, the board's audit committee will engage an independent regulatory advisory firm to undertake a review of the corporation's credit risk policies and practices, including an evaluation of the adequacy of the corporation's policies and practices for identifying, assessing, and managing credit and underwriting risks. The independent advisor will make recommendations on how to strengthen the corporation's credit and underwriting risk policies and practices.

17:11 EDT Alpine Immune Sciences says feasible to engage CD28 for cancer immunotherapy - Alpine Immune Sciences announced the oral presentation of results from the dose-escalation portion of NEON-1, NCT04186637, a first-in-human, dose-escalation and expansion study of davoceticept monotherapy in participants with advanced malignancies, at the 2022 Annual Meeting of the American Association for Cancer Research, AACR. Highlights from the presentation include: Despite a highly heterogeneous, heavily pretreated, advanced solid tumor population - the majority classically considered to be unresponsive to immunotherapy - 11 of 48 evaluable participants demonstrated tumor volume reduction; 26 achieved clinical benefit as defined as a best response of stable disease or better; Three remained on treatment beyond 6 months. Two partial responses were observed in colorectal and renal cell carcinoma. Davoceticept was well-tolerated with no reported events of cytokine release syndrome. Adverse events of interest included immune-related adverse events and infusion-related reactions, the majority of which were grades 1-2. A single dose-limiting toxicity of gastritis was observed at 3 mg/kg, but a maximum tolerated dose was not reached. Immunophenotyping demonstrated favorable increases in activated and central memory T cells, as well as reductions in regulatory T cells. Overall, pharmacodynamic analyses suggest 1 or 3 mg/kg every 3 weeks as the optimal biological dose. Monotherapy expansion cohorts in metastatic cutaneous melanoma, renal cell carcinoma, and PD-L1-positive tumors are planned. "These results indicate that it is indeed feasible to engage CD28 for cancer immunotherapy, and further suggest that this approach may be clinically advantageous, even for heavily pretreated cancers," remarked Stanford Peng, MD PhD, Alpine's President and Head of Research and Development. "We eagerly look forward to advancing to expansion cohorts as soon as possible."

17:02 EDT Osisko Gold reports Q1 attributable GEOs roughly 18,251 - Osisko Gold Royalties provided an update on its first quarter 2022 deliveries, sales, cash margins and recent asset advancements. Osisko earned approximately 18,251 attributable gold equivalent ounces in the first quarter of 2022. This figure excludes 3,025 GEOs earned from the Renard diamond stream. As expected, production in the first quarter was impacted by the coldest months of the year, which reduced production at the Eagle mine. Production is expected to increase in the coming quarters as that seasonal effect dissipates and as ramp up of the Mantos expansion progresses. In addition, proceeds from the Renard diamond stream are not expected to be reinvested into the bridge loan starting in early May and, as such, revenues will be recognized again as attributable GEOs. Osisko recorded preliminary revenues from royalties and streams of C$50.7M during the first quarter and preliminary cost of sales of C$3.2M, resulting in a record quarterly cash margin of C$47.5M, or approximately 94%. Osisko will provide full production and financial details with the release of its first quarter 2022 results after market close on Wednesday, May 11th, 2022, followed by a conference call on Thursday, May 12th at 8am ET. More details are provided at the end of the release.

16:40 EDT TreeHouse appoints Scott Ostfeld of JANA Partners to board - TreeHouse Foods announced the appointment of Scott Ostfeld, Partner of JANA Partners and Co-Portfolio Manager of its engaged investing strategy JANA Strategic Investments, to the TreeHouse Foods Board of Directors. The appointment is in connection with an agreement with JANA Partners , which owns approximately 9.2% of TreeHouse Foods' outstanding common stock."The TreeHouse Board and JANA share a common appreciation regarding the opportunity for TreeHouse Foods, and we are united behind the shared goal of enhancing value for our stockholders and other stakeholders," said Ann M. Sardini, Chair of the Board. "As a shareholder, Scott understands our company and our industry well. His appointment to the Board follows continued, constructive engagement with JANA and reflects our commitment to pursuing the best path towards maximum value creation." Mr. Ostfeld commented, "TreeHouse Foods is an incredibly attractive company well-positioned to benefit from favorable secular tailwinds and with multiple avenues to unlock and drive shareholder value. I am appreciative of the Board's continued engagement, and I am excited to work alongside Steve and all of the other TreeHouse Foods directors to enhance value for all stockholders." Steve Oakland, Chief Executive Officer and President, said, "Over the past several years, TreeHouse Foods has made meaningful progress against our strategic goals to support our customers, simplify our structure and enhance our supply chain as we capitalize on the strong, long-term demand for private-label food and TreeHouse Foods products. I welcome Scott to the Board and look forward to working with all of our directors as we continue to drive value for our customers and deliver improved results." Mr. Ostfeld will join the Board as a Class III director, with a term expiring at the TreeHouse Foods 2023 annual meeting of stockholders. Following his appointment, the TreeHouse Foods Board will be comprised of eleven directors.

16:34 EDT NanoString falls 28% to $23.60 after Q1 revenue guidance cut

16:31 EDT Cable One announces CFO transition plan - Cable One announced that its Board of Directors has appointed Todd Koetje as its next CFO. Koetje will succeed Steven Cochran as CFO effective July 1. Cochran will continue to serve as the Company's CFO through June and as a Senior Vice President during July, after which he is expected to serve as a consultant to the Company through early January 2023. Koetje and Cochran will continue to work closely together during the planned orderly transition. Koetje, who currently serves as the Company's Senior Vice President, Business Development and Finance, brings more than 20 years of capital markets, telecom industry and financial leadership experience. Prior to joining Cable One in September 2021, Koetje served as Managing Director & Group Head of the Technology, Media & Telecommunications Leveraged Finance team for Truist Securities.

16:26 EDT BRT Apartments acquires remaining JV interest in two communities for $12.8M - BRT Apartments "announced that it completed the acquisition of the remaining interests in joint ventures that own two multi-family properties with an aggregate of 462 units. The purchase price for these interests was $12.8M and because these properties are wholly owned, the Company will include the assets and liabilities of these properties on its consolidated balance sheet, including the aggregate mortgage debt currently on these properties of, as of March 31, 2022, $56.7M, with a weighted average remaining term to maturity of, 8.4 years, and a weighted average interest rate of 4.04%. In aggregate, these two properties contributed approximately $150,000 of equity in loss of unconsolidated joint ventures in 2021."

16:21 EDT Mercury Systems receives $14M order from defense prime contractor - Mercury Systems announced it received a $14M order from a defense prime contractor to provide system-in-package, or SiP, assemblies for an airborne secure processing application. The order was received in the company's Q3 and is expected to be delivered over the next several quarters.

16:19 EDT Southwestern Energy increases borrowing base to $3.5B - Southwestern Energy announced that it has entered into an Amended and Restated Credit Agreement, dated April 8, 2022 , which amends the Company's Credit Agreement, dated April 26, 2018. The Amended Credit Agreement, among other things, extends maturity date of $3.5B reserve-based credit facility by three years to April 2027 and increases the borrowing base to $3.5B. The company also maintains elected commitments of $2.0B.

16:18 EDT Angi Inc. reports March ads and leads down 7% - 2022 Monthly Year-over-Year Growth Trends through March. Reports March Angi ads and leads down 7% YoY. Reports total March revenue up 9% YoY. Reference Link

16:16 EDT Procter & Gamble raises quarterly dividend to 91.33c per share - The Board of Directors of The Procter & Gamble Company declared an increased quarterly dividend of 91.33c per share on the Common Stock and on the Series A and Series B ESOP Convertible Class A Preferred Stock of the Company, payable on or after May 16, 2022, to Common Stock shareholders of record at the close of business on April 22, 2022, and to Series A and Series B ESOP Convertible Class A Preferred Stock shareholders of record at the start of business on April 22, 2022. This represents a five percent increase compared to the prior quarterly dividend.

16:14 EDT IAC reports March Angi Inc. total revenue up 9% from last year - As part of its March monthly metrics disclosure, IAC also reports Dotdash Meredith revenue up 634%, pro-forma Dotdash Meredith revenue down 6%, and its Search business revenue up 14% from last year. Emerging & Other revenue was up 13% from last year. Reference Link

16:11 EDT PayPal CFO John Rainey to depart, Gabrielle Rabinovitch named interim CFO - PayPal (PYPL) announced the departure of John Rainey, PayPal's CFO and executive vice president, Global Customer Operations. After almost seven years at PayPal, Rainey is leaving the company to join Walmart (WMT) as its CFO. To support an orderly transition, Rainey will remain at PayPal until late May. PayPal's Board of Directors has launched a formal search process to identify Rainey's permanent replacement. PayPal's Board of Directors has approved the appointment of Gabrielle Rabinovitch, senior vice president, Corporate Finance and Investor Relations, as interim CFO effective upon Rainey's departure. The Global Customer Operations team will join the Risk, Legal and Customer Operations organization led by Executive Vice President Aaron Karczmer.

16:10 EDT CTS Corporation to acquire Ferroperm Piezoceramics for DKK 525M cash - CTS Corporation and Meggitt, also known as Ferroperm Piezoceramics, have announced a definitive Share Purchase Agreement under which CTS would acquire Meggitt A/S for Danish Krone 525M in cash, subject to net debt and working capital adjustments and the other terms and conditions of the Share Purchase Agreement. The transaction is expected to close in 2022 and is subject to the receipt of the requisite regulatory approvals, as well as the satisfaction of other customary closing conditions. Founded in 1952, Ferroperm specializes in the design and manufacture of high performance piezoceramic components for use in complex and demanding medical, industrial, and aerospace applications. The company is recognized for its high quality and innovative piezoceramic technology. Based in Kvistgaard, Denmark, Ferroperm has established a strong customer base across Europe and North America. "Ferroperm represents a great addition to our expanding piezoceramic business and advances ourdiversification," said Kieran O'Sullivan, CEO of CTS Corporation. "Strategically, both organizations focus on serving targeted markets that demand high quality material formulation, reliability and technical depth. Ferroperm's presence in medical therapeutics is complementary to our existing focus on medical imaging and diagnostics. We are excited to welcome a capable team with deep technical expertise to the CTS family."

16:07 EDT Safe Bulkers to buy 2012-built, Chinese, dry-bulk, 181,000 dwt, Capesize - Safe Bulkers announced that it has entered into an agreement for the acquisition of a 2012-built, Chinese, dry-bulk, 181,000 dwt, Capesize class vessel, to be named MV Michalis H, with a scheduled delivery date within May 2022. The vessel will be acquired at a gross purchase price of $30.0 million and will be financed from the cash reserves of the Company.Dr. Loukas Barmparis, President of the Company, commented: "We have further expanded in the Cape market segment acquiring our seventh vessel, at what we believe a competitive purchase price, utilizing our liquidity."

16:06 EDT Good Times Restaurants reports Q2 SSS down 0.9% - Good Times Restaurants announced that same store sales for its second quarter ended March 29, 2022 decreased 0.9% for its Good Times brand from the same prior year quarter and increased 15.5% for its Bad Daddy's brand from the same prior year quarter. Average weekly sales during the 2022 second quarter among restaurants open for at least 18 months were $25,469 for the Company's Good Times restaurants and $50,405 for the Company's Bad Daddy's restaurants.

16:04 EDT ION Geophysical trading halted, news pending

16:02 EDT Cirrus Logic names Venk Nathamuni CFO - Cirrus Logic announced the appointment of Venk Nathamuni as chief financial officer, effective April 18, 2022. Venk brings more than 30 years of experience with deep knowledge of the semiconductor industry, corporate finance and strategy, business development, mergers and acquisitions, and investor relations, the company said. "Venk brings an outstanding combination of technical, corporate development and investor relations expertise coupled with considerable experience on Wall Street," said John Forsyth, Cirrus Logic president and chief executive officer. "I am excited to partner with him and believe he will be a great asset to Cirrus Logic as we continue to drive our business forward into new areas of growth." Venk joins Cirrus Logic from Arista Networks, where he served as head of corporate finance, M&A, investor relations, and information technology.

16:02 EDT Navidea receives acceptance letter from NYSE American - As previously disclosed, on January 28, 2022, Navidea Biopharmaceuticals received a notification from the NYSE American stating that the Company was not in compliance with the $6.0 million stockholders' equity requirement of Section 1003(a)(iii) of the NYSE American Company Guide. As required by the NYSE American, the Company submitted a plan to the NYSE American by February 28, 2022 advising of actions it has taken or will take to regain compliance with the continued listing standards by July 28, 2023. On April 8, 2022, the Company received notification from the NYSE American that the Company's plan to regain compliance was accepted. The Acceptance Letter also stated that the Company is also not in compliance with Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide, which require an issuer to have stockholders' equity of (i) $2.0 million or more if it has reported losses from continuing operations and/or net losses in two out of its three most recent fiscal years, and (ii) $4.0 million or more if it has reported losses from continuing operations in three out of its four most recent fiscal years. The Acceptance Letter noted that the Company had stockholders' equity of $624,743 as of December 31, 2021 and has reported net losses from continuing operations in its five most recent fiscal years ended December 31, 2021. The NYSE American has granted the Company a plan period through July 28, 2023 to regain compliance with Sections 1003(a)(i), (ii) and (iii). If the Company is not in compliance with all continued listing standards by that date or if the Company does not make progress consistent with the plan during the plan period, the NYSE American may commence delisting procedures. Navidea's common stock will continue to be listed on the NYSE American while it attempts to regain compliance with the listing standards noted, subject to Navidea's compliance with other continued listing requirements.

14:58 EDT CFPB sues TransUnion, calls ''out-of-control repeat offender' - The Consumer Financial Protection Bureau filed a lawsuit against TransUnion, two of its subsidiaries, and executive John Danaher for violating a 2017 law enforcement order. "The order was issued to stop the company from engaging in deceptive marketing, regarding its credit scores and other credit-related products. After the order went into effect, TransUnion continued its unlawful behavior, disregarded the order's requirements, and continued employing deceitful digital dark patterns to profit from customers. The Bureau's complaint also alleges that TransUnion violated additional consumer financial protection laws," the agency said in a statement. "TransUnion is an out-of-control repeat offender that believes it is above the law," said CFPB Director Rohit Chopra. As alleged in the complaint, TransUnion "used an array of dark patterns to trick people into recurring payments and to make it difficult to cancel them." The lawsuit alleges that TransUnion violated the Consumer Financial Protection Act of 2010 by failing to implement requirements of the Bureau's 2017 order "and by engaging in deceptive acts and practices." The CFPB is seeking monetary relief for consumers, such as restitution or return of funds, disgorgement or compensation for unjust gains, injunctive relief, and civil money penalties. Shares of TransUnion are down 1% to $93.65 in afternoon trading.

14:11 EDT Post Holdings reports avian influenza at Nebraska facility - Post Holdings provided information regarding an avian influenza incident at one of Michael Foods' owned egg-laying facilities. Post said that, today, a Michael Foods owned egg-laying flock in Nebraska tested positive for avian influenza. The facility houses approximately 2 million egg-laying hens, or approximately 4% of Post's controlled supply, inclusive of third party contracted farms.

13:59 EDT Huadi International Group Company Ltd trading resumes

13:32 EDT TransUnion calls CFPB claims 'meritless' - In response to a complaint filed by the Consumer Financial Protection Bureau, TransUnion issued the following statement: "The claims made by the CFPB against TransUnion and John Danaher, a former executive, are meritless and in no way reflect the consumer-first approach we take to managing all our businesses. In January 2017, TransUnion entered into a consent order with the CFPB relating to how it markets TransUnion Credit Monitoring, a subscription product that offers consumers credit monitoring and identity theft protection services, as well as access to their credit scores. Shortly thereafter, as required by the consent order, TransUnion submitted to the CFPB for approval a plan detailing how it would comply with the order. The CFPB ignored the compliance plan, despite being obligated to respond and trigger deadlines for implementation. In the absence of any sort of guidance from the CFPB, TransUnion took affirmative actions to implement the consent order.We have been in compliance with our obligations and we remain in compliance with the consent order today. Rather than providing any supervisory guidance on this matter and advising TransUnion of its concerns - like a responsible regulator would - the CFPB stayed silent and saved their claims for inclusion in a lawsuit, including naming a former executive in the complaint. Despite TransUnion's months-long, good faith efforts to resolve this matter, CFPB's current leadership refused to meet with us and were determined to litigate and seek headlines through press releases and tweets. The CFPB's unrealistic and unworkable demands have left us with no alternative but to defend ourselves fully. Over the last several years, and under the direction of new leadership, TransUnion has led the credit reporting industry in making significant changes aimed at benefitting consumers and increasing transparency in the credit reporting process."

13:04 EDT Vertical Aerospace trading resumes

13:02 EDT Gain Therapeutics reports 'positive' data on GT-02287 in Parkinson's - Gain Therapeutics presented new pre-clinical data from its Parkinson's Disease program. The results were highlighted in a poster presentation at the 2022 Synuclein Meeting being held April 12 - 15, 2022, in Leuven, Belgium. The data show that the the lead compound GT-02287 increases the levels and activity of the beta-glucocerebrosidase protein, improves lysosomal health, corrects abnormal phenotypes of PD including alpha-synuclein, and most importantly improves neuronal network connections and neuron survival. Eric Richman, Chief Executive Officer of Gain comments, "The data we presented at the Synuclein Meeting demonstrates further encouraging disease modifying potential for patients with Parkinson's disease who currently have no effective treatment options." "Our lead candidate, identified with the proprietary SEE-Tx drug discovery platform, can allosterically bind and stabilize GCase, thus avoiding its degradation and allowing its transport to the lysosomes where the enzyme can carry out its biological function," said Manolo Bellotto, Ph.D., President and General Manager of Gain. "The new data builds on a body of evidence showing a beneficial effect of our lead candidate on enzyme levels, substrate depletion, lysosomal health, and most importantly for disease pathology, neuronal health." The data was generated in two different in vitro models covering both WT and the two most pathogenic GBA1 mutations L444P and N370S. The models used are the BE2-M17 dopaminergic neuron model which is implicated in Parkinson's disease pathology, and a CBE model of rat mescencephalic neurons which induces the aggregation of alpha-synuclein as well as neuronal cell death.

12:47 EDT AEye strength attributed to report speculating company as possible target - Shares of AEye are up 50c, or 10%, to $5.78 in afternoon trading after Dealreporter stated, according to contacts, that a sector advisor suggested that the LIDAR maker's capital-light, high-margin model could make it "an attractive takeover target."

12:00 EDT Scor ADR falls -8.1% - Scor ADR is down -8.1%, or -46c to $5.25.

12:00 EDT Myovant Sciences falls -21.3% - Myovant Sciences is down -21.3%, or -$2.96 to $10.91.

12:00 EDT Blue Apron rises 12.3% - Blue Apron is up 12.3%, or 48c to $4.37.

11:49 EDT Gap says unvaccinated employees must wear masks - Gap said in a statement, "After reviewing the CDC's guidance, along with other current COVID data trends, we made the decision to adjust our mask policy across our Gap, Old Navy, Banana Republic, and Athleta stores in the U.S. This includes the following: All employees who are not fully vaccinated are required to wear masks when working in our stores, HQ offices and Customer Experience Centers (formerly known as distribution centers); We recommend that customers who are not fully vaccinated wear masks in our stores, except in jurisdictions where masks are required by law. Other aspects of our in-store health and safety practices will remain intact for the time being. Customers can also shop our brands online or via our Curbside Pickup service where available. At this time, we are not making changes to our policies in Canada, Mexico or other international locations." Reference Link

11:33 EDT RYAH Group board nominates David Richards as CEO, director - The RYAH Group Board of Directors announced that Dr. David Richards has been nominated as Director and CEO of RYAH Group Inc., subject to approval by the Canadian Securities Exchange Richards' previous senior leadership roles include Nortel Networks' GM Global Data; GM Global Supercarriers; GM UK Switching; Global ThinkQuest Champion at Oracle's Education Foundation; CEO of Ellis Jones Solicitors; Executive Director of Business Development and Marketing, AECC University College; Senior Vice President and Director of the Dorset Chamber of Industry and Commerce; Board Director of the West Hants Lawn and Tennis Club, and various other organizations. Gregory Wagner has resigned from the Board of Directors and as CEO of the Company to pursue new professional opportunities.

11:12 EDT General Motors, Glencore enter multiyear cobalt supply agreement - Glencore (GLNCY) and General Motors (GM) announced a multi-year sourcing agreement in which Glencore will supply GM with cobalt from its Murrin Murrin operation in Australia. Cobalt is an important metal in the production of EV batteries, and the cobalt processed from Australia will be used in GM's Ultium battery cathodes, which will power electric vehicles such as the Chevrolet Silverado EV, GMC HUMMER EV and Cadillac LYRIQ. Both Glencore and General Motors are members of the Responsible Minerals Initiative, and Glencore's Murrin Murrin operation is conformant with the OECD-aligned Responsible Minerals Assurance Process.By the end of 2025, GM plans to have capacity to build 1 million electric vehicles in North America, and has announced a series of actions to create a new and more secure EV supply chain. Reference Link

11:02 EDT Fifth Third CEO Greg Carmichael to retire, Tim Spence to succeed - Fifth Third Bancorp announced that Greg Carmichael has elected to retire as CEO effective July 5. At that time, Carmichael will become executive chairman, continuing to lead the Board of Directors and provide advice and counsel to the CEO. Tim Spence will succeed Carmichael as Fifth Third's CEO. Spence joined Fifth Third in 2015 as chief strategy officer. Prior to being named president in 2020, he was head of consumer bank, payments and strategy.

10:43 EDT Mascoma Bank selects Alkami as digital banking platform partner - Alkami Technology announced that Mascoma Bank has selected Alkami's digital banking platform as part of a full technology stack overhaul with core banking technology firm Thought Machine.

10:32 EDT Bally's to purchase minority stake in Snipp Interactive for $5M - Snipp Interactive announced that a subsidiary of Bally's Corporation has signed an agreement to invest $5M in Snipp. As part of the Investment, Bally's will be entitled to nominate one director to Snipp's board of directors, which is expected to be increased in size to five directors. Bally's will also be provided with a right of first refusal in respect to any offer to purchase all or substantially all of Snipp's assets received by Snipp from any competitor of Bally's. Completion of the Investment is subject to the approval of the TSX Venture Exchange as well as the satisfaction of other customary closing conditions. Following completion of the Investment, Bally's is expected to own approximately 9% of the issued and outstanding common shares of Snipp, having subscribed for 25,000,000 common shares of Snipp at 20c per share as part of the Investment. Bally's and Snipp will also enter into commercial agreements whereby Bally's will become Snipp's exclusive gaming partner for Snipp's loyalty gaming platform, recently acquired in connection with Snipp's February 22, 2022 acquisition of Gambit Rewards, Inc. As part of the Commercial Arrangements, Bally's will also receive a three-year term license of the SnippLOYALTY software platform at arm's length rates, intended for implementation across Bally's physical and online properties. In addition, Bally's will be granted an option to license the source code for the specific version or versions of the SnippLOYALTY software platform actually implemented in any of Bally's properties for a price of $10M.

10:12 EDT Twitter acquires OpenBack; terms not disclosed - Jay Sullivan, head of consumer product at Twitter, said via the platform that Twitter has acquired OpenBack, a mobile platform "that helps make apps more engaging through device-side control of push notifications." Sullivan said that "OpenBack and their talented team joining Twitter will help us improve our ability to deliver the right notifications at the right time, in a way that puts people's privacy first. We're thrilled to have them join the flock and look forward to seeing their impact." Reference Link

10:00 EDT Scor ADR falls -6.3% - Scor ADR is down -6.3%, or -36c to $5.35.

10:00 EDT Myovant Sciences falls -18.8% - Myovant Sciences is down -18.8%, or -$2.60 to $11.27.

10:00 EDT Calix rises 7.5% - Calix is up 7.5%, or $2.81 to $40.48.

09:47 EDT Daily S&P Biotech Bear 3x Shares falls -5.7% - Daily S&P Biotech Bear 3x Shares is down -5.7%, or -$2.12 to $35.05.

09:47 EDT Myovant Sciences falls -22.6% - Myovant Sciences is down -22.6%, or -$3.13 to $10.74.

09:47 EDT Party City rises 6.3% - Party City is up 6.3%, or 22c to $3.72.

09:44 EDT Karooooo says 'strong momentum' in subscribers carried through in FY22 - Karooooo, which owns 100% of Cartrack Holdings, announced that "the growing demand by small to large enterprises wanting to digitally transform their business to remain competitive prevailed throughout 2022." The company stated: "Despite persistent changing and challenging operating conditions, Karooooo's operational resilience, coupled with its profitable and robust business model drove new customer additions," delivering growth in the total number of subscribers to 1,525,972 subscribers in total for 2022, up 17% from a 2021 total of 1,306,000, and 219,972 net subscriber additions for 2022, up 23% from 179,485 added in 2021. "It is encouraging that in our first year as a NASDAQ listed company, our subscriber growth for 2022 was in line with our growth outlook. I am pleased with Karooooo's resilience and execution despite the persistent operating headwinds resulting from the Covid-19 pandemic during the period," commented Karooooo founder CEO, Zak Calisto. Karooooo will report financial results for the fourth quarter and full year ended February 28 on Wednesday, April 27, the company noted.

09:36 EDT Worksport, Hyundai America Technical Center enter production agreement - Worksport Ltd. (WKSP) and Hyundai America Technical Center (HYMTF) executed a letter of understanding in which both parties agreed that Worksport would produce prototypes of the Worksport SOLIS and a modified version of the COR energy storage system based on the Hyundai Santa Cruz's bed geometry. HATCI, a division of Hyundai Motor Company, has provided to Worksport 3D Data specifically for the Project. The two companies intend to explore the benefit of each other's products working in tandem in order to determine the viability of a future partnership. A tentative timeline was also agreed upon for the Project whereby the working SOLIS and COR models for Hyundai's yet to be announced vehicle would be ready for presentation to Hyundai's head office by October of 2022.

09:33 EDT MyMD Pharmaceuticals announces preclinical data on MYMD-1 - MyMD Pharmaceuticals announced positive new preclinical study data demonstrating the potential effectiveness of MYMD-1 for the treatment of rheumatoid arthritis. MYMD-1 demonstrated a significantly greater anti-inflammatory effect than current TNF-alpha inhibitors on the market, the top three of which represent an estimated $31 billion market. The comparative study of arthritis, using the CAIA model, was conducted and analyzed by Charles River Laboratories International, a full-service contract research organization for drug discovery and development. Study results showed that MYMD-1 inhibited inflammation more effectively in the RA model by 30% and 70% of the top two marketed drugs, respectively. The company said, "In addition to the greater efficacy shown in the preclinical model of RA, we believe that MYMD-1 holds significant advantages over current anti-TNF-alpha therapies: Smaller molecular size with easy access throughout the body, including the brain; Selective inhibition of TNF-alpha production by lymphocytes involved in autoimmune disease, but not macrophages involved in front line immune protection against bacteria and viral infections; Not shown to cause serious side effects in preclinical studies that is common with traditional therapies that treat inflammation; Simultaneous inhibition of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-17; and Ease of oral dosing rather than by needle injection. Drug candidate MYMD-1 is the only TNF-alpha inhibitor that is dosed orally." MyMD is currently conducting a Phase 2 clinical trial of MYMD-1 as a therapy for delaying aging and expanding healthy lifespan. The primary endpoint for the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in circulating levels of TNF-alpha within 28 days of therapy. In addition to aging and rheumatoid arthritis, MYMD-1's distinct action in regulating the immune system and treating chronic inflammation is being developed for the treatment of multiple sclerosis, diabetes, and inflammatory bowel disease.

09:26 EDT EzFill signs fleet fueling agreement with nexAir - EzFill Holdings announced a new fleet agreement with nexAir, effective immediately. EzFill will provide regular mobile fuel service for nexAir's Miami location, which also serves as its Florida centralized warehouse. The family-built company provides specialty gases, welding equipment, and other supplies to area customers through its fleet of trucks. Deliveries include anhydrous ammonia, carbon monoxide, fuel gas, and sustainable gas cylinders.

09:24 EDT Lucid Group up 4% after announcing start of Air Grand Touring deliveries - Shares of Lucid Group are up 4% in pre-market trading at $22.56 after the company announced that it has started deliveries of Lucid Air Grand Touring model with an MSRP of $179,000.

09:23 EDT Quintessential Brands adopts Cyren Inbox Security - Cyren announced Quintessential Brands has adopted Cyren Inbox Security to reduce the cybersecurity risks associated with the most common attack vector - email.

09:21 EDT Tyler Technologies extends payment solutions contract with Texas - Tyler Technologies, announced that the state of Texas has extended its contract for Tyler's payment services. The three-year agreement builds upon the existing 13-year relationship with Tyler's NIC Division. Serving Texans since 2009, Tyler's NIC Division provides payment processing and settlement services for 235Texas.gov applications, enabling online payments and over-the-counter credit, debit, and Automated Clearing House payments on behalf of 306 government entities. As part of the new agreement, Tyler will integrate its Data & Insights platform into the payment processing and settlement services, bringing advanced analytics to the solution, allowing clients to easily digest information and better understand customers' transactions. Since September 1, 2018, Tyler's NIC Division has securely processed more than 73.5 million transactions totaling more than $5.69B for the state of Texas.

09:19 EDT IDW Media announces results of 2021 annual meeting - IDW Media Holdings hosted their annual meeting on April 5, 2022. At the meeting, the shareholders re-elected Howard S. Jonas as Chairman of the Board, as well as Sanford S. Climan, Perry Davis, Allan I. Grafman, Amy Jonas, Irwin Katsof and Christopher McGurk as directors; approved an amendment to the IDW Media Holdings 2019 Stock Option and Incentive Plan; and ratified the appointment of Zwick CPA, PLLC as the Company's independent registered public accounting firm for the fiscal year ended October 31, 2022. Additionally, Chief Executive Officer Ezra Y. Rosensaft and Chief Financial Officer Brooke Feinstein provided an update on the progress the Company made during 2021 and an overview of the go-forward strategy. Below is an abbreviated summary of their comments: Mr. Rosensaft stated, "2021 was a pivotal turnaround year that set the groundwork to drive sustained, long-term value for our shareholders. We accomplished an incredible amount of heavy lifting in 2021, revitalizing our strategy with an aggressive focus on producing new original content, strengthening the management team, transforming our balance sheet with an equity capital raise and paying our debt down to zero, and listing our stock on the NYSE American. The core of IDW's business is creating and developing stories that captivate audiences by leveraging our powerful content development platform. Over the past few years, we have achieved notable milestones including: Publishing over 280 comics and 125 graphic novels annually. 5 shows currently streaming on various streaming services including Netflix. Carefully building a team of 80 of the best professionals in the sector. Worked with 450 authors and illustrators. Scooped up approximately 40 Eisner Awards. Today, IDW Publishing is the fourth largest direct market publisher of comics and graphic novels. Publishing currently has about 40 original titles in various stages of development and a library of over 100 titles. In 2021, we grew the pipeline of this part of our business substantially. In addition, we continue to publish for iconic brands including Disney, Marvel and DC Comics. This important business generates stable cash flows that we leverage to grow our base of original titles. In our entertainment division, we develop, produce and distribute the amazing stories that are created in our publishing division. We have already had a number of our projects streamed on Netflix, BBC and AMC, and our goal is to have 3 to 5 per year. Across our business, a key transformation in 2021 was the significant de-risking of our model. Previously, we made big bets on shows and financed them by adding leverage to the balance sheet. Having learned some valuable lessons, we've changed our approach to minimize risk and generate more predictable cash flows. The refined model creates value as we: Profitably build a valuable library of content -- approximately 75% of our original titles at least break even in our publishing division. Leverage our content library on the entertainment side of our business to generate pure incremental profit of $1 to $3 million per season per show. Create a virtuous cycle where successful entertainment vehicles drive additional publishing sales with merchandising opportunities and reciprocal use of IP across divisions. Moreover, as the media industry further consolidates and Disney, Valiant, DC Comics and other large players gobble up the remaining smaller independent players, we have become one of the few integrated, independent original content focused media companies remaining in the market. Strategically, this further highlights the value of our rapidly growing original content library and our outstanding reputation as an independent shop for creators. enabling us to continue to attract excellent creative partners. We've started 2022 with an exceptionally strong first quarter financial performance, and our balance sheet remains solid and debt free with ample liquidity to pursue growth initiatives and continue to build our original IP library."

09:17 EDT Banxa Holdings reports March TTV of A$81M - BANXA Holdings has announced its March 2022 TTV, recording AUD $81 million. For the quarter ending March 31, 2022, the Company recorded a 71% year-on-year increase compared to the same reporting period in 2021, growing from AUD $207 million to AUD $355 million, in line with the market conditions. In March, Banxa added 9 new partners to its network, including Paxful, the large well-known peer-to-peer exchange platform with over six million users, Pionex the automated trading leader driven by crypto trading bots, and 1Inch, the top 10 DEX aggregator and a key player in the DeFi space. These new partners provide significant growth opportunities and great exposure to existing and emerging markets. The business also added 13 new coins across ten chains, including the highly anticipated APE, CAKE and AXS. Adding these new coins solidifies Banxa's mission to bridge the gap between the fiat and crypto worlds, creating more access points for millions of consumers worldwide to enter the cryptocurrency market. Banxa has also announced the departure of Dave Malcolm as the Company's Chief Marketing Officer. Dave was a steady guiding force for the company from its early days. Chloe Sasson, Banxa Chief of Staff, will be stepping into the role for the interim. Banxa has also announced that it has granted 40,000 Options to an officer of the Company. The Options vest over 24 months, have an expiry of 5 years and are exercisable at CAD $2.50 The Company has engaged the services of Generation IACP to provide services as a market maker in compliance with the policies and guidelines of the TSX Venture Exchange and other applicable legislation. Generation will receive a fee of CAD $7,500 plus applicable taxes per month.

09:15 EDT Secarna says Evotec achieves program designation in Bristol Myers collaboration - Secarna Pharmaceuticals reports that its collaboration partner Evotec (EVO) has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (BMY) triggering a payment of $16M to Evotec. The programme further adds to a fast-growing pipeline in neurodegeneration that also includes EVT8683, which entered clinical development end of 2021. In contrast to previously nominated programmes, which are small molecule based, the newly designated project utilises an antisense-based approach. Evotec is eligible to receive tiered royalties of up to low double-digit percentages of sales of any commercial products resulting from the collaboration with Bristol Myers Squibb. Additionally, Evotec can earn up to $250M in development and sales milestones within the collaboration. Antisense oligonucleotides are precisely engineered chemical structures that specifically bind to a targeted RNA to interfere with gene expression. By specifically inhibiting the production of disease-driving proteins in the cells of interest, ASOs can provide new pathways to tackle targets that are difficult to regulate or were previously deemed "undruggable". The programme leverages ASOs originating from the LNAplus ASO discovery and development platform established and validated by Secarna Pharmaceuticals with whom Evotec entered a strategic partnership in August 2020.

09:12 EDT HUMBL, artist Monty drop multimedia NFT with music, video, merchandise - HUMBL announced the drop of his first NFT on the HUMBL Gallery slated for April 12, 2022. The drop reflects a collaboration between HUMBL and Monty to deliver an NFT that also provides access to experiences and chances to win merchandise and tickets to upcoming shows. "HUMBL is excited to partner with Monty on this groundbreaking initiative," said HUMBL CEO, Brian Foote. "At HUMBL, we believe that blockchain will converge multimedia NFTs, tickets and fan experiences into new forms of engagement between artists and audiences. Today we take another step forward towards delivering this Web 3 reality into the global marketplace."

09:11 EDT Beyond Meat expands availability of Beyond Chicken Tenders - Beyond Meat (BYND) announced that it is significantly increasing the availability of its Beyond Chicken Tenders at leading retail outlets across the country, including supermarkets, pharmacies and club stores. Starting today, Beyond Chicken Tenders are available at select Albertsons (ACI), CVS (CVS), Sprouts (SFM) and Whole Foods Market stores nationwide, and are expanding into all Kroger (KR) banners throughout April. "Building on the positive momentum of our recent chicken launches, we're excited to significantly expand the availability of our Beyond Chicken Tenders by showing up in more places for our consumers - from their favorite supermarket or drugstore, to large warehouse clubs - making delicious, nutritious and sustainable plant-based meat more accessible than ever before," said Deanna Jurgens, Chief Growth Officer, Beyond Meat.

09:09 EDT Kulicke & Soffa, PDF Solutions collaborate on manufacturing solutions - Kulicke and Soffa Industries (KLIC) and PDF Solutions (PDFS) announced their existing relationship is expanding to address the challenges of production system control and variability reduction in semiconductor assembly and packaging. The Kulicke & Soffa, K&S, and PDF Solutions collaboration is intended to combine assembly Fault Detection and Classification, FDC, data, collected by K&S' RPM data-enabled tools, with artificial intelligence and machine learning capabilities from PDF Solutions' Exensio platform. The unification of RPM and Exensio analytic capabilities is being designed to enable insights to directly enhance advanced assembly issue dispositioning and containment, driving yield and efficiency gains for customers. In addition to these production benefits, this collaboration is also intended to help alleviate the ongoing chip shortage. These combined capabilities are being architected to also identify out-of-control process and equipment issues before they require unanticipated downtime, enhancing system throughput and delivering more chips to market from existing manufacturing capacity.

09:08 EDT Kulicke & Soffa and PDF Solutions expand relationship - Kulicke and Soffa Industries (KLIC) and PDF Solutions (PDFS) announced their existing relationship is expanding to address the challenges of production system control and variability reduction in semiconductor assembly and packaging. As more companies adopt innovative packaging and assembly technologies to bring new products to market, it has become essential to apply smart manufacturing methods to identify the root cause of packaging and assembly issues that impact product yield, quality, and cost. The Kulicke & Soffa and PDF Solutions collaboration is intended to combine assembly Fault Detection and Classification, or FDC, data, collected by K&S' RPM, data-enabled tools, with artificial intelligence and machine learning capabilities from PDF Solutions' Exensio platform.

09:06 EDT Nuvei announces partnership with nextmarkets - Nuvei announces its partnership with nextmarkets. Through its proprietary payment platform, Nuvei will help solidify nextmarkets' capabilities in the markets they already operate in, as well as power their expansion outside of Europe, as they continue to democratize the trading experience for people around the world. "nextmarkets' vision to enable all investors, regardless of experience to achieve financial success in their online trading activities by combining innovative technology with powerful expert knowledge, is aligned with our own," said Nuvei Chair and CEO Philip Fayer. "Uniting payment technology and consulting, we help businesses remove payment barriers and increase acceptance rates. We are excited to partner with nextmarkets to aid their international expansion," he added.

09:06 EDT MasterCard, Interos launch partnership - Mastercard announced a new partnership with Interos, the hyper-growth operational resilience company, to further expand its security strategy and bring Interos' multi-tier risk monitoring capabilities to financial institutions. This new offering allows organizations to proactively detect and eliminate risk across multiple areas - including cyber, financial, ESG, restrictions, geopolitical and operational - throughout their network of business and merchant relationships.

09:05 EDT NextPlay Technologies integrates NextTrip booking engine with Fareportals - NextPlay Technologies and Fareportal announce the integration of the NextTrip ConNextions booking engine into CheapOair, an online travel agency. CheapOair can now offer its users the ability to easily search, book and confirm reservations from a few million alternative lodging rental properties around the world. Tim Sikora, NextTrip President and COO, commented, "Our ConNextions booking engine integration with CheapOair dramatically expands our North America reach by allowing their travel agents and customers to dynamically package Vacation Rentals with flights to global destinations on over 600 airlines and hundreds of car rental companies. We see our global inventory of vacation rental properties providing many new lodging options to CheapOair customers around the world. We look forward to expanding this relationship with others in Fareportal's huge network of brands, agencies and customers."

09:02 EDT Progenity to change name to Biora Therapeutics in Q2 - Progenity announced that it will change its name to Biora Therapeutics during the second quarter of 2022, to better reflect the company's focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics. "As we complete our strategic transformation, we are launching Biora Therapeutics to reflect our mission going forward, which is to reimagine therapeutics and their delivery," said Adi Mohanty, Chief Executive Officer. "By creating innovative smart pills designed for targeted drug delivery to the GI tract and for systemic, needle-free delivery of biotherapeutics, we are developing therapies to improve patients' lives." Progenity expects the brand launch for Biora Therapeutics to coincide with the company's Q1 2022 earnings call in May, and the company's NASDAQ ticker symbol will also change from "PROG" to "BIOR" at that time.

09:02 EDT MongoDB announces pay-as-you-go offering on Google Cloud - MongoDB (MDB) announced the launch of a pay-as-you-go MongoDB Atlas offering, which can be launched directly from the Google (GOOG, GOOGL) Console. The offering provides developers with a simplified subscription experience, and enterprises more choice in how they procure MongoDB on Google Cloud. With this new pay-as-you-go MongoDB Atlas offering, customers only pay for the resources they use and can scale based on their needs, with no up-front commitments while using their Google accounts. This offering will also make it easier for customers to build, scale, and manage data-rich applications with MongoDB Atlas within the Google Cloud Console.

08:59 EDT Personalis publishes HLA LOH data in nature Communications - Personalis announced the publication of its study titled, "A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity," in Nature Communications. Human leukocyte antigen loss of heterozygosity, or HLA LOH, allows cancer cells to escape immune recognition by deleting HLA alleles, causing the suppressed presentation of tumor neoantigens. Despite its importance in immunotherapy response, few methods exist to detect HLA LOH, and their accuracy is not well understood. Further, detecting HLA LOH accurately from sequencing data is of interest given the growing ubiquity of tumor molecular profiling. The Personalis study details the development of DASH, a novel machine learning-based algorithm to detect HLA LOH from paired tumor-normal sequencing data. Through validation with cell line mixtures and patient-specific digital PCR, the study demonstrates increased sensitivity of HLA LOH detection by DASH compared to previously published tools and paves the way for clinical utility. Using DASH for 610 patients across 15 tumor types, the study found that a large percentage of patients are impacted by HLA LOH, including patients with non-small cell lung cancer adenocarcinoma, cervical cancer and head and neck squamous cell carcinomas. Additionally, the study showed inflated HLA LOH rates compared to genome-wide LOH, and correlations between CD274 expression and microsatellite instability status, suggesting that HLA LOH is an immune resistance strategy.

08:54 EDT Nascent Biotech, BioTools partner to define PTB's higher order structure - Nascent Biotech has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure. Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTool's groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification. PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding and the more extensive, 3-dimensional results have dramatic impact on the molecule's pharmaceutical effectiveness.

08:49 EDT Commercial Vehicle Group says back to 100% of pre-invasion output rates - CVG had 1,200 employees immediately impacted by the senseless Russian invasion of Ukraine. Despite a complete shut-down initially, CVG is back to 100% pre-invasion output rates. This quick response was possible thanks to brave leadership by its local team, the resolve and creativity of the Ukrainian and neighboring Czech Republic teams, fast-acting customers, and CVG's decision to implement fallback production positions with two new production facilities in the Czech Republic and a supply chain from Mexico. CVG's local leaders are Jan Chabera, Executive Director of CVG's Operations in Eastern Europe, and Yaroslav Pauk, Director of CVG Ukraine. They have led the implementation of the following actions in response to the invasion: All employees were initially paid, even if unable to work. Overtime wages were provided for all employees who went to work. All employees were issued a spot bonus while the facility was closed. Upgrades to the bomb shelter near our L'viv facility, fitted with a bathroom and kitchenette, and can house up to 300 people during an air raid/siren. Modified 24/7 work schedules to reduce the number of people in the facility at one time and maintain output. Upgraded the IT infrastructure to defend against cyber-attacks. Workstation modifications will be made for any injured employee wishing to return to work. Assistance will be provided for any employee who wishes to move to or from the Ukraine. All sales to customers in Russia and Belarus have been halted. CVG and its Ukraine team are deeply committed to persevering through this ordeal together. CVG's plant in L'viv, Ukraine immediately shut down and then reconstituted itself quickly, despite having all eligible male employees called into military service. CVG reestablished a team of more than 1,000 mostly female employees in the facility. They are dedicated to staying in Ukraine, protecting the local GDP, producing products for customers, and maintaining their communities and country. CVG has moved quickly with its customers who are equally committed to protecting and preserving Ukraine, but additionally need to achieve supply chain certainty. This has required extremely fast customer-supplier decision-making. CVG is thankful to all those that have helped it move fast. CVG will continue to fully support the Ukrainian government, economy and people, and urges other organizations with operations in Ukraine to follow suit in ensuring the safety of its employees in the region, but also to preserve their way of life as best possible. In order to provide backup production to Ukraine, CVG immediately decided to begin fallback production in the Czech Republic. CVG has an existing team, distribution, plants, and banking in the Czech Republic and was able to open two new plants in parallel within a few weeks. The "CVG 35" led the way - 35 brave women who traveled from Ukraine through Poland to the Czech Republic to help establish the new facilities, despite not speaking the Czech language or knowing the fate of their homes. CVG provided a moving package, apartments and furnishings to this core group of Ukrainian women to relocate to the Czech Republic. Thanks to these women, a large CVG support team, and the expedient movement of equipment and raw materials, the Czech plants are now operational. They are already producing electrical harnesses for electric vehicles and passenger cars. With this startup success, CVG plans to increase employment to 350 people between the two new locations.

08:46 EDT Sanuwave Health announces new board leadership - SANUWAVE Health (SNWV) announced three new board members will join as one departs. The new board members Ian Miller, Jeffrey Blizard, and Jim Tyler will begin their terms in Q2 2022. Ian Miller: Commercial Vice President of Hoogwegt US. Jeffrey Blizard: Senior Director of Sales at AbioMED (ABMD). Jim Tyler: Advisory partner to Morgan Stanley Expansion Capital. Additionally, SANUWAVE announces John Nemelka will depart from the board.

08:44 EDT Ocugen announces clinical hold on Phase 2/3 study of COVAXIN - Ocugen announced that the Company was informed by the U.S. Food and Drug Administration that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN, OCU-002, on clinical hold. This is a result of the Company's decision to voluntarily implement a temporary pause in dosing participants of OCU-002 while it evaluates statements made by the World Health Organization following their inspection of Bharat Biotech International Limited's manufacturing facility. We will work with the FDA to address any questions.

08:43 EDT Acer Therapeutics, Relief announces presentation of ACER-001 data - Acer Therapeutics (ACER) and its collaboration partner, Relief Therapeutics (RLFTF), announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of taste-masked sodium phenylbutyrate, ACER-001, compared to sodium phenylbutyrate powder during poster sessions at the recent Society for Inherited Metabolic Disorders, SIMD, Annual Meeting on April 10-13, 2022. "We are highly encouraged by the results of these bioavailability, bioequivalence and taste attribute studies of ACER-001," added Raghuram Selvaraju, Chairman of Relief. "We look forward to the U.S. Food and Drug Administration's decision on the Prescription Drug User Fee Act target action date on June 5, 2022."

08:42 EDT Exela Technologies adds mobile to suite of payment solutions with global bank - Exela Technologies announced Exela has expanded its 30-year relationship with a tier one global bank by adding mobile payment processing. Our customer currently uses Exela for payments, fraud detection and mortgage processing. This multi-year XBP contract will be included in ITPS, Exela's largest reporting segment. Exela's exchange for bills and payment solutions can be deployed to bridge the gap between traditional and digital banking providing choice and scale. The mobile solution will fully manage mobile payments conforming to rules and best practices from Pay.UK, the UK's primary payments body.

08:40 EDT Genasys initiates shipments of new LRAD 950NXT - Genasys announced the first shipments of its LRAD 950NXT, the Company's most advanced integrated communication, surveillance, security, and response system to date. "The world is becoming more dangerous as geo-political turmoil, regional conflicts, and infrastructure disruptions are increasing in intensity and frequency," said Richard Danforth, Chief Executive Officer of Genasys. "The 950NXT utilizes our proprietary technology to identify and interact with potential threats from a safe distance to provide defense forces and security personnel more time and information to accurately assess situations and appropriately scale responses. $1.8 million in previously announced LRAD 950RXL orders received from the French Navy instigated the development of our next generation 950NXT," continued Danforth. "In addition to the French Navy's order change to 950NXT systems, the Spanish Navy placed a $1.4 million 950NXT order last month." Danforth added, "We're experiencing strong interest and order demand for our newest, most advanced LRAD system. Along with the naval forces orders from France and Spain, order commitments for super-yachts, and from critical infrastructure facilities, including ports, utilities, and dams have also been received."

08:39 EDT CACI gets $258M task order from defense agencies initiative program office - CACI International was awarded a task order worth $258M to expand its enterprise technology support and continue modernization efforts to the Defense Agencies Initiative, DAI, program office's financial management and end-to-end business processes. Awarded under the Defense Logistics Agency's J6 Enterprise Technology Services indefinite delivery, indefinite quantity contract, the task order continues CACI's current enterprise technology support to modernize Department of Defense business systems, ensuring DoD agencies participating in DAI meet evolving business, technology, security, and control requirements. The company will support DAI's process areas, including acquire to retire , cost accounting , user management , time and labor , procure to pay , budget to report , budget formulation, order to cash , proposal to reward , governance, risk, and compliance , and resale accounting. CACI will also advance and improve DAI's processes and procedures with the latest technologies to offer software and DevSecOps at-scale throughout the enterprise. John Mengucci, CACI President and Chief Executive Officer, said, "As a trusted partner, CACI has worked in lock-step with DAI to bring the best technologies at scale to improve business processes for the DoD agencies and United States Marine Corps (USMC) they represent. CACI specializes in providing distinctive enterprise resource planning tools to transform how U.S. Government works, ultimately reducing technical debt and saving time, cost, and resources spent on future technology investments."

08:37 EDT Stifel, Eaton Partners team with RCP Advisors to launch Twelve Degrees - Stifel Financial (SF), Eaton Partners, a Stifel Company, and RCP Advisors, a subsidiary of P10 (PX), announced the launch of Twelve Degrees, a strategic partnership focused on investing in and providing capital solutions to leading emerging and first-time alternative investment fund managers. Twelve Degrees will combine Eaton's capabilities as one of the largest global placement agents and financial advisory firms with RCP's access to lower-middle-market private equity fund managers. Twelve Degrees will provide flexible capital solutions, strategic advice, back-office infrastructure, access to broader Stifel banking services, and global distribution, capital formation, and marketing capabilities designed to help emerging and first-time managers build and scale their businesses. These services will be provided in exchange for GP-level economics. Using a selective, data-driven, and long-term approach, the partnership will use institutional best practices and sourcing channels across both firms.

08:36 EDT Personalis issued U.S. patent related to MRD platform NeXT Personal - Personalis announced the issuance of a U.S. Patent related to its minimal residual disease, or MRD, and recurrence platform, NeXT Personal. The patent, U.S. Patent No. 11,299,783, entitled "Methods and Systems for Genetic Analysis," was issued on April 12. The '783 patent claims novel methods for a partially personalized assay, combining both tumor-informed and prespecified content. Tumor-informed methods can provide high sensitivity for detection of MRD. They can also support tracking of variants specific to an individual patient's cancer, such as those targeted by specific therapies or which are thought to elicit an immune response. Prespecified, tumor-naive content can include variants not detected on initial sequencing of a tumor, but which may emerge and confer drug resistance as a tumor evolves. It can also include driver mutations of a second primary tumor, which may arise independently during the course of the initial cancer. The '783 patent is a member of a patent family that broadly describes Personalis' foundational work relating to the development of personalized assays for disease identification and tracking.

08:35 EDT Newmont to buy remaining 5% interest in Yanacocha from Sumitomo for $48M - Newmont Corporation has announced that it will acquire the remaining 5% interest in Yanacocha from Sumitomo Corporation for $48M. The transaction is expected to close in the second quarter, making Newmont the exclusive owner-operator of this world-class asset. This announcement follows an announcement in February 2022, in which Newmont acquired Buenaventura's 43.65% interest in Minera Yanacocha. "This transaction gives Newmont full equity ownership of the Yanacocha district where we are positioning the Sulfides project for profitable production and value generation for decades to come. We have deep knowledge of the asset and the value it brings to Newmont stakeholders," said Newmont President and CEO Tom Palmer. "We are committed to continuing to be a catalyst for sustainable development in Peru and look forward to continuing to work closely with communities in the Cajamarca region and the Peruvian government." The acquisition of the Buenaventura and Sumitomo ownership positions is consistent with Newmont's district consolidation strategy. Newmont continues to advance the Sulfides project, which is progressing toward a full-funds decision later this year. The Sulfides project will increase Newmont's copper production, supporting the transition to a green economy, and will extend mine life for decades to come," noted the statement.

08:34 EDT IM Cannabis' CEO and founder acquires 150.000 common shares of the company - Oren Shuster, CEO, director and founder of IM Cannabis announces that he has acquired an aggregate of 150,000 common shares in the capital of IMCC in a series of open market transactions between April 5 and 8 through the facilities of the Nasdaq Capital Market. Shuster acquired the Common Shares at an average price of $2.238 per Common Share for an aggregate purchase price of $335,731.60. Immediately prior to the Acquisition, Shuster held beneficial ownership of, or control or direction over, 9,135,137 Common Shares, representing 13.11% of the issued and outstanding Common Shares on a non-diluted basis and 14.71% of the Common Shares on a partially diluted basis. As a result of the Acquisition, Shuster now holds beneficial ownership of, or control or direction over, an aggregate of 9,285,137 Common Shares, representing approximately 13.32% of the issued and outstanding Common Shares on a non-diluted basis and 14.93% of the Common Shares on a partially diluted basis.

08:33 EDT Assure Holdings announces new partnership with Yankee Alliance - Assure Holdings announced a new partnership with Yankee Alliance, a member-driven healthcare group purchasing organization. This partnership will enable Yankee Alliance members to take advantage of pricing and terms pre-negotiated by Yankee Alliance for Assure's Joint Commission accredited IONM services. "We are honored to have been selected to partner with Yankee Alliance and share their objectives of financial, clinical, and operational effectiveness for surgeons and hospitals," said John Farlinger, Assure's executive chairman and CEO. "Assure is looking forward to delivering industry-leading intraoperative neuromonitoring and remote neurology services to Yankee Alliance clients."

08:32 EDT IO Biotech announces initiation of Phase 2 IOB-022 / KN-D38 trial - IO Biotech (IOBT) announced that it has dosed the first patient, in metastatic non-small cell lung cancer, NSCLC, in its Phase 2 IOB-022 / KN-D38 trial. The IOB-022 / KN-D38 trial seeks to evaluate IO Biotech's lead candidate, IO102-IO103, in combination with KEYTRUDA, Merck's (MKR) anti-PD-1 therapy, in previously untreated patients with three different tumor types in the first line setting -NSCLC, squamous cell carcinoma of the head and neck, and urothelial bladder cancer. "Initiating this study with IO102-IO103 further progresses our late-stage development program," said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. "We believe IO102-IO103 has the potential to show utility for multiple cancer indications. We look forward to expanding our dataset in these additional indications."

08:31 EDT HEXO, Tilray enter agreement for strategic alliance - HEXO Corp. (HEXO) announced that the Company has taken a significant step forward in executing on its strategic plan - The Path Forward - by entering into definitive agreements with Tilray Brands, Inc. (TLRY), as well as entering into a definitive equity purchase agreement (with an affiliate of KAOS Capital, further to the Company's press release of March 3, 2022. Closing of the transaction with Tilray Brands and the Standby Agreement is expected to occur by the end of May 2022, subject to the satisfaction or waiver of closing conditions. The definitive agreements with Tilray Brands solidify the strategic partnership between HEXO and Tilray Brands and, on closing, will provide HEXO with a recapitalized balance sheet and the enhanced financial flexibility critical to accelerating its transformation into a cash flow positive business within the next four quarters. The terms of the transaction are set out in a transaction agreement entered into among HEXO, Tilray Brands and HT Investments MA providing for the amendment to the terms of the outstanding senior secured convertible note originally issued by HEXO to HTI and the execution of an amended and restated Note with HTI that will be immediately thereafter assigned to Tilray Brands pursuant to the terms of an assignment and assumption agreement. HEXO and Tilray Brands have also committed to work together to evaluate cost saving synergies as well as other production efficiencies and to set out the terms of such arrangements in certain commercial agreements to be entered into upon the closing of the Transaction. The Commercial Agreements are expected to create significant efficiencies, with a target combined cost savings of up to $80 million within two years to be shared equally between the two companies. The Standby Agreement with KAOS Capital permits HEXO to demand that the Standby Party subscribe for an aggregate of C$5 million of common shares in the capital of HEXO per month over a period of 36 months for aggregate proceeds of up to C$180 million over the term of the Standby Agreement. Under the terms of the Transaction Agreement, Tilray Brands has agreed to acquire 100% of the remaining outstanding principal balance, currently US$193 million, of the Amended Note originally issued by HEXO to HTI, subject to certain conditions described below. As consideration for Tilray Brands' purchase of the Amended Note, Tilray Brands will pay HTI 95% of the principal for the Amended Note that will be outstanding at closing. Until closing, HTI may continue to redeem the Note pursuant to its terms, however in no event shall the principal of the Amended Note be less than US$160 million prior to the closing of the Transaction. As consideration for the Amended Note, HEXO will issue to HTI a number of Common Shares equal to 12% of the outstanding principal of the Amended Note as at the closing, divided by US$0.54. In the event this would result in HTI owning more than 9.99% of HEXO's Common Shares as of the closing, the Company will issue a number of rights exercisable for Common Shares equal to the difference between the number of Common Shares that would have been issued but for the Blocker Threshold and the number of Common Shares actually issued. The Transaction Agreement provides for, among other things, HEXO's right to consider, between the date of signature and closing, a proposal that is superior to the Transaction in certain circumstances and a right in favour of Tilray Brands to match any such superior proposal. The Transaction Agreement also provides for the payment by HEXO to Tilray Brands of a termination fee in certain circumstances. In addition, the Transaction Agreement provides that, under certain circumstances, where the Transaction is not completed because of the failure of HEXO to obtain the approval of its shareholders for the Transaction, HEXO would be required to reimburse Tilray Brands' expenses up to US$3,000,000. The Transaction Agreement also provides that Tilray Brands will have the right to nominate one director to HEXO's board of directors as well as one board observer for so long as Tilray Brands holds at least 1% of HEXO's Common Shares. Among the various amendments to be made to the Note, the maturity date will be extended by three years to May 1, 2026, providing HEXO with significantly greater financial runway. The Amended Note will bear interest during the term at a rate of 5% per year. During the first year, interest will be payable in cash and during the second to fourth years of the term, the interest can, at HEXO's discretion, be added to the principal amount of the Amended Note if HEXO meets certain liquidity conditions. The initial conversion price will be C$0.85, which, as of April 12, 2022, implies that Tilray Brands would have the right to convert the Amended Note into approximately 37% of the outstanding Common Shares of HEXO not including other equity issuances associated with the Transaction at closing. The Purchase Price will be satisfied in cash, common shares of Tilray Brands, or a combination thereof. The closing of the Transaction is subject to the satisfaction of a number of conditions, including:receipt of approvals from the Toronto Stock Exchange and the Nasdaq Stock Market; receipt of shareholder approval from the HEXO shareholders; no material adverse effect having occurred in respect of HEXO; and receipt of all consents and approvals required by any regulatory authorities, including from the Competition Bureau.

08:30 EDT 8i Acquisition 2 Corp trading resumes

08:24 EDT Nautilus appoints Weld as CPO, Wilcox as VP of Affinity Reagent Development - Nautilus Biotechnology (NAUT) announced the appointments of Gwen Weld as Chief People Officer, CPO, and Sheri Wilcox, Ph.D., as Vice President, VP, of Affinity Reagent Development. Gwen Weld brings to Nautilus more than 25 years of senior leadership in human resources, organizational culture, and business strategy. Immediately prior to joining the company, Weld served as Interim Chief People Officer at Amperity. Sheri Wilcox, Ph.D., joins Nautilus from SomaLogic (SLGC) and most recently served as Senior Director of Global Scientific Engagement.

08:21 EDT Green Plains releases 2021 sustainability report - Green Plains released its 2021 Sustainability Report, outlining environmental, social and governance priorities, progress and targets. Specifically, the report highlights the significant progress already achieved toward Green Plains' commitment to carbon neutrality in operational emissions by 2050, enhanced governance practices, enhanced diversity in workforce recruitment practices and expanded safety best practices. Notably, the company conducted a comprehensive materiality assessment in conjunction with the report, to ensure alignment with stakeholder ESG priority areas. "The materiality assessment included in our second sustainability report highlights our dedication to the elements of ESG that are highest priorities to our key internal and external stakeholders," said Todd Becker, President and Chief Executive Officer. "Customers, employees and investors want to know that we are focused on producing low-carbon ingredients, reducing our overall environmental footprint and providing a safe work environment. With each year's sustainability report, our ESG focus will continually evolve with increasing transparency and accountability." The following achievements and enhancements are outlined in the 2021 report: 35% reduction in operational emissions from 2018 baseline; 24% decrease in OSHA Total Recordable Incident Rate from 2020; Alignment with the Task Force on Climate-related Financial Disclosures; Increased focus on natural capital, biodiversity and land stewardship.

08:20 EDT QSAM Biosciences receives Japanese patent for CycloSam - QSAM Biosciences announced that the Japan Patent Office has granted a key patent that protects the use of "lower specific activity" Samarium-153 in conjunction with the treatment of bone cancer in children and adults. This patent covers within the Japanese market the "high purity therapeutic bone agents" technology exclusively licensed to QSAM on a worldwide basis, and relates to the novel manner in which the Samarium-153 used in CycloSam is produced. That process reduces long-lived impurities -- namely Europium-154 -- which may allow for higher and multiple dosing regimens in the treatment of different types of bone cancer, including cancer that has metastasized from the lung, breast or prostate. Those types of metastasized bone cancer are the subject of QSAM's current FDA-cleared Phase 1 clinical trial, which has already begun recruiting and screening patients. Management believes that multi-dosing regimens may be the key to CycloSam being able to successfully treat bone tumors, and is advancing it clinical trials toward that goal.

08:19 EDT MediWound's EscharEx highlighted in presentation at SAWC Spring 2022 - MediWound announced that clinical data from the Company's EscharEx phase 2 trials was highlighted in a poster and oral presentation at the 35th Symposium on Advanced Wound Care Spring Conference. The abstract poster was one of ten posters, out of the 235 posters presented, to be selected for certificate and featured during the Poster Grand Rounds session of the SAWC spring conference. The poster entitled: "Results from an Ongoing Open Phase 2 Study Assessing the Safety, Efficacy and Pharmacological Effects of Bromelain-based Enzymatic Debridement on Biofilm, Microbial loads and Cytokines in patients with DFU and VLU," featured data from an ongoing Phase 2 study that showed EscharEx to debride wounds and promote wound area reduction, while reducing biofilm and bacterial bioburden safely and effectively. EscharEx was also featured in an oral presentation entitled: "Introduction to EscharEx: An Innovative Enzymatic Solution for the Debridement of Hard to Heal Wounds," during an educational symposium, where several key opinion leaders highlighted the importance of debridement in wound management and the unmet medical need. They also covered the efficacy and safety data from the Company's two well controlled clinical studies in patients with venous leg ulcers and diabetic foot ulcers, in addition to a case series from a clinical phase 2 pharmacology study demonstrating EscharEx's fast and effective debriding activity accompanied with reduction in biofilm and bacterial load.

08:18 EDT Caladrius treats first patient in Phase 1b trial of CLBS201 - Caladrius Biosciences announced that the first patient has been treated in its Phase 1b open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease at the Clinical Advancement Center in San Antonio, Texas. CLBS201 is an investigational autologous CD34+ cell therapy product for administration directly into the renal artery to reverse or slow the decline of renal function in diabetic patients with rapidly progressive chronic kidney disease.

08:16 EDT Codexis, Molecular Assemblies announce results of first collaboration - Codexis and Molecular Assemblies announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA. Using a highly evolved DNA polymerase, developed by Codexis, to enable its Fully Enzymatic Synthesis technology, select companies and institutions will be able to access a Key Customer Program that is slated to begin later this year. The Fully Enzymatic Synthesis technology developed by Molecular Assemblies employs a template-independent DNA polymerase, terminal deoxynucleotidyl transferase, which has the ability to synthesize much longer DNA sequences with fewer errors in an aqueous solution. Naturally occurring TdT has many limitations to commercial use. In order to accelerate innovation for the field, Molecular Assemblies and Codexis partnered in 2020 to engineer an enzyme to deliver differentiated and cost-effective solutions for the fully enzymatic synthesis of DNA. John Nicols, Codexis' President and CEO, said, "The successful completion of this first collaboration with Molecular Assemblies has resulted in a highly evolved version of TdT polymerase that delivers unparalleled coupling efficiency and speed at elevated temperatures. We believe the ability to exclusively deploy this proprietary enzyme will significantly differentiate Molecular Assemblies' Fully Enzymatic Synthesis technology from not only other emerging players but also the current industry-standard phosphoramidite chemistry method."

08:16 EDT Toast and eCard expand partnership - eCard Systems announced an expanded partnership with Toast. eCard Systems originally partnered with Toast in 2019 for online gift card and merchandise ordering and manufacturing services. The new integration adds access to eCard's digital, online and physical gift card transaction processing and program management

08:13 EDT Cocrystal reports preliminary data from Phase 1 initial cohorts with CC-42344 - Cocrystal Pharma reported preliminary results of a Phase 1 study with CC-42344, demonstrating a favorable safety and pharmacokinetic profile. CC-42344 is a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza A with a novel mechanism of action. The ongoing Phase 1 clinical trial plans to enroll 56 healthy adults. Results from the first two single-ascending dose 100 mg and 200 mg cohorts showed a favorable pharmacokinetic profile of CC-42344. To date, CC-42344, has demonstrated excellent oral bioavailability, dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. The Phase 1 study is designed to evaluate CC-42344 administered in single-ascending and multiple-ascending doses. Cocrystal expects to report full results from the study in 2022. "Today's update reinforces Cocrystal's progress in developing best-in-class antiviral medicines. Influenza is one of the most serious worldwide public health threats. Important concerns remain about the emergence of pandemic strains and resistance to available drugs. We are encouraged by the safety and pharmacokinetic profile observed to date with single oral doses of CC-42344 and look forward to initiating the next portion of the trial," said Sam Lee, Ph.D., Cocrystal's President and co-interim CEO. "Based on a novel mechanism of action and high barrier to resistance, we believe CC-42344 could provide a potentially best-in-class oral candidate for the treatment of pandemic and seasonal influenza infection."

08:13 EDT ProKidney announces updated design for REACT Phase 3 program - ProKidney announced the updated design for its REACT Phase 3 program. REGEN-006 and REGEN-016 are expected together to enroll up to 1,200 subjects with CKD on optimized standard of care in two Phase 3 trials. The FDA has indicated that these trials may be sufficient to support regulatory filing of a Biologic License Application for its transformational cell therapy for CKD if they meet the primary and key secondary endpoints. Subjects will be randomized 1:1 into either a REACT treatment arm and undergo a kidney biopsy or a sham control arm. The primary objective of each study is to assess the efficacy of up to two REACT injections given three months apart and delivered into biopsied and non-biopsied contralateral kidneys using a minimally invasive percutaneous approach. The primary composite endpoint is the time from first injection to the earliest of: at least 40% reduction in eGFR, using the 2009 CKD-EPI serum creatinine equation, sustained for 30 days; or eGFR less than15 mL/min/1.73m using the 2009 CKD-EPI serum creatinine equation, sustained for 30 days and/or chronic dialysis, and/or renal transplant; or renal or cardiovascular death. A new Phase 2 trial will be opened to eligible subjects from the sham arms of the Phase 3 trials to allow them access to REACT treatment after completing the trial or experiencing a qualifying event that would require the subject to discontinue participation in the trial. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III.

08:10 EDT Guess board refutes Legion's view of Marciano, says last letter 'regugitation' - Guess?, In issued the following statement in response to Legion Partners' open letter to Guess shareholders: "Legion Partners' latest letter is just a regurgitation of previously reported and previously addressed grievances they have against the Company. While Legion is entitled to their own opinions and views, they are not entitled to create their own false narrative for the benefit of their campaign. Legion seems bent on recycling false and misleading information, while we are focused on executing our transformation strategy and driving our strong business performance, both of which Legion has complimented. As previously disclosed in 2018, the Guess Board of Directors established a Special Committee, comprised entirely of independent directors and advised by independent legal counsel, to conduct a comprehensive investigation, the findings of which were made public. Regarding the post-2018 allegations against Paul Marciano, the independent members of the 2018 Special Committee continue to serve on the Board and were fully briefed. The Company has strongly refuted these claims and is contesting them vigorously. In January 2022, Legion delivered a Demand for Board Action. The Board promptly created a committee of independent directors to investigate the subject matter of the demand, including the post-2018 allegations. With the assistance of independent legal counsel, the Demand Review Committee will evaluate the proper response to the Demand after it completes its investigation."

08:09 EDT Unity Biotechnology completes enrollment in BEHOLD study - UNITY Biotechnology has completed enrollment for the BEHOLD study, its Phase 2 clinical trial of UBX1325 in patients with diabetic macular edema, DME. "Patients with advanced retinovascular diseases, including DME, shoulder a significant burden with current standard-of-care that usually requires regular doctor visits for frequent injections of anti-VEGF treatment, often as frequently as every 8 weeks," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "Given the encouraging activity we've observed in patients with DME after a single injection of UBX1325 in our Phase 1 study in patients no longer considered responsive to anti-VEGF treatment, we're optimistic that UBX1325 can potentially provide an entirely novel therapeutic option and lessen the current burden on both patients and physicians as a durable senolytic treatment. We are very pleased to have completed enrollment and see this as a significant milestone in the UBX1325 clinical program. We look forward to building on this momentum and anticipate 12-week results from our Phase 2 DME study, BEHOLD, by mid-year and 24-week results by the end of the year."

08:07 EDT Elys Game Technology partners with All Bets to establish allBETS DC One - Elys Game Technology announced a partnership with All Bets to establish allBETS DC One and operate a sportsbook planned to open at 821 Upshur St. NW, in Washington, D.C. The company's subsidiary, USBookmaking, will provide sport wagering services to manage the sportsbook risk and provide trading services. Following the launch of Grand Central Restaurant and Sportsbook, in the Adams Morgan area, and with the Cloakroom DC currently in regulatory review, the partnership with allBETS DC would represent the company's third implementation of its strategy to offer a sportsbook solution in non-conventional locations such as restaurant and bar venues in Washington, DC. And, if awarded a license, allBETS DC is believed to be a groundbreaking venture by an African-American woman owned sports wagering business.

08:06 EDT Mobiquity selected by Affinity to provide data, advertising solutions - Mobiquity Technologies announced it has been selected by Affinity to provide data and programmatic advertising services for the purpose of promoting brand awareness of their Affinity Token and ADAPT utility. Sean Trepeta, President of Mobiquity Networks, said "It has been a very exciting time at Mobiquity as our crypto-core and crypto-curious audience grows every day. We are excited to see companies like Affinity use our audience to build their brand and become trusted names in the crypto community."

08:06 EDT Homeowners of America introduces services in Wyoming, Nebraska - Homeowners of America announced the launch of services in Wyoming and Nebraska. This marks the Company's fourth and fifth extension of services this year as part of its nationwide expansion plan. Previous 2022 launches include Missouri, New Mexico, and Montana.

08:05 EDT 8i Acquisition 2 Corp. enters business combination agreement with EUDA Health - EUDA Health Limited and 8i Acquisition 2 Corp. (LAX) announced that they have entered into a definitive business combination agreement that will result in EUDA Health Limited becoming a publicly listed company. Upon the close of the transaction, LAX will be renamed EUDA Health Limited and is expected to remain listed on NASDAQ under the new ticker symbol "EUDA". The companies said, "EUDA Health operates a first-of-its-kind Southeast Asian healthcare analytics platform dedicated to customer-centric solutions that increase access to quality care, improve patient outcomes, and reduce costs. The company's ecosystem-based approach serves a full spectrum of healthcare needs, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and after care services. Leveraging its end-to-end expertise in healthcare management, EUDA Health's proprietary unified AI platform connects patients, insurers, and medical professionals to the necessary data to triage conditions and digitally connect with medical professionals for personalized treatment protocols that optimize patient outcomes and ongoing care. EUDA Health is poised to disrupt the multi-trillion dollar Southeast Asia healthcare industry where healthcare expenditures continually outpace GDP growth and efficient access to comprehensive care is uncertain. Southeast Asia has seen accelerated adoption of healthcare IT, with usage increasing by 400% in 2020 alone. EUDA Health aims to be an industry leader throughout this transition. Where patients once waited hours to see a doctor for ten minutes, EUDA Health's platform strives to connect patient members to medical experts within five minutes on average, alleviating an overburdened system and enhancing the patient experience. Since its founding in 2019, EUDA Health has grown tremendously and is expected to operate across five countries- Singapore, Malaysia, Vietnam, India and Indonesia- by the end of 2022. Through its innovative and dynamic solutions, EUDA Health has developed a diversified revenue stream and gained clear line-of-sight into sustainable growth through both geographic expansion and enhanced service offerings." The combined company will have an estimated post-transaction enterprise value of $583 million, consisting of an estimated equity value of $673 million and $90 million in net cash, assuming no redemptions of 8i public stockholders. Cash proceeds raised will consist of 8i's approximately $86.3 million of cash in trust. Additional earnouts in the form of 9 million total shares will be awarded post-transaction close if EUDA's share price reaches $15, $20 and $25 over three years. Proceeds from the trust account is expected to be used for product development and other AI technology research, business expansion and potential strategic investment and acquisition opportunities. EUDA's growth strategy is expected to generate estimated revenue and adjusted EBITDA of $200 million and $43 million, respectively, in 2023. The transaction with EUDA Health is a related party transaction. Mr. Tan, LAX's CEO and Chairman of the Board, is a 10% shareholder of Watermark Developments Limited, the sole shareholder of EUDA Health. Watermark will roll 100% of its equity into the combined company and will own approximately 82% of the combined company's outstanding ordinary shares on a pro forma basis mmediately after the closing. EverEdge Global has been engaged to render a fairness opinion on the fairness of the transaction to LAX from a financial point of view. The business combination has been unanimously approved by the boards of directors of both EUDA Health and LAX and is expected to close in the fourth quarter of 2022, subject to regulatory and shareholder approvals, and other customer closing conditions.

08:04 EDT Everi Holdings partners with Scarlet Pearl Casino Resort - Everi Holdings announced its subsidiary, Everi Payments Inc., is now live with a leading solution for the liquidity of crypto currencies, B4U Financial, at the Scarlet Pearl Casino Resort on Mississippi's Gulf Coast. Through Everi's financial access solutions, the B4U Financial crypto currency solution allows casino patrons the ability to convert digital currency into cash. Additional integration capabilities include casino operators' ability to track the disbursement of cash through the B4U API to the owners' existing systems in real time. This capability is enhanced by Everi's real-time monitoring tools and remote diagnostics features, which provide greater uptime with quicker response and resolve times.

08:02 EDT AbbVie announces data from Phase 2 trial of navitoclax - AbbVie announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting. Navitoclax is an investigational, first-in-class, oral BCL-XL/BCL-2 inhibitor that is designed to activate programmed cell death in cancer cells. Navitoclax and its safety and efficacy are under evaluation as part of ongoing Phase 2 and registrational Phase 3 studies. Myelofibrosis is a rare, difficult-to-treat blood cancer that results in excessive scar tissue formation, or fibrosis, in the bone marrow. Anti-fibrosis activity, measured by reversal of bone marrow fibrosis, or BMF, and reduction in driver gene variant allele frequency, or VAF, have been suggested as potential biomarkers to measure disease modification in myelofibrosis, but their association with a survival benefit have not been widely described.1 These data build on AbbVie's history of transforming standards of care in blood cancers with significant unmet needs. The results presented at AACR 2022 were from REFINE - a Phase 2 trial evaluating navitoclax in combination with ruxolitinib, which included patients with myelofibrosis who had progressed on or had a suboptimal response to at least 12 weeks of ruxolitinib monotherapy. Median exposure to prior ruxolitinib was 91 weeks in the first 34 patients enrolled earlier in the trial. In the exploratory analysis of 32 patients who were evaluable for improvements in BMF, 12 had a greater than or equal to1 grade improvement during any time point in the study. For driver gene VAF reduction, 26 patients were evaluable and 6 (23%) achieved a greater than or equal to20% reduction at week 24. Five patients achieved both BMF and VAF responses.

08:02 EDT Regency Centers announces COO retirement, succession plan - Regency Centers announced forthcoming changes to its executive management team. Jim Thompson, Executive Vice President and Chief Operating Officer, has announced his retirement, effective December 31, 2022. Concurrently, the Company announces the following executive management promotions, effective January 1, 2023: Alan Roth, currently Senior Managing Director, East Region, will become Executive Vice President, National Property Operations and East Region President. Nick Wibbenmeyer, currently Senior Managing Director, West Region, will become Executive Vice President, West Region President.

07:55 EDT 8i Acquisition 2 Corp trading halted, news pending

07:52 EDT Tilray enters agreement with HEXO related to Senior Secured Convertible Note - Tilray Brands (TLRY) announced that the Company has signed a definitive agreement for a commercial and financial partnership with HEXO Corp. (HEXO). As initially announced on March 3, 2022, the partnership will bring together Canada's top two cannabis market leaders, strengthening their respective operations and setting the stage for production efficiencies, which are expected to yield increased productivity and other efficiencies amid intensely-competitive market dynamics. Under the terms of the agreement, and subject to the satisfactory completion of certain closing conditions, Tilray Brands will acquire 100% of the remaining $193M outstanding principal balance of the senior secured convertible note that was issued by HEXO and held by funds affiliated with HT Investments. The Note will be amended to include conversion rights at a price of C$0.85 per HEXO Share, which would allow Tilray Brands to acquire a significant equity ownership position in HEXO and participate directly in its considerable growth opportunities. As previously announced, the strategic alliance between Tilray Brands and HEXO, the final terms of which are subject to negotiation and execution of the commercial agreements described below, is expected to provide several financial and commercial benefits, including: Accretion and Flexibility: the acquisition of the Note by Tilray Brands is expected to be immediately accretive to the Company. The agreement provides that HEXO will pay Tilray Brands an annual fee of $18M for advisory services with respect of cultivation, operations, and production matters. The terms of the Note, as amended, provide that the Note shall bear interest at a rate of 5% per annum, beginning on the date of Transaction closing. In addition, Tilray Brands shall have the flexibility to either be paid the principal amount of the Note plus any accrued interest and payment-in-kind upon the maturity of the Note or, prior to maturity, convert such amount into a substantial ownership position in HEXO. Substantial Synergies: the strategic alliance between Tilray Brands and HEXO is expected to deliver up to $80M of cost synergies and other efficiencies within two years of the completion of the Transaction, which will be shared equally subject to certain agreed upon adjustments. Both companies have been working collaboratively together to evaluate cost saving synergies as well as other production efficiencies, including with respect to cultivation and processing services, certain Cannabis 2.0 products, including pre-rolls, beverages and edibles, as well as shared services and procurement. Strengthening Product Innovation for International Markets: Tilray Brands and HEXO would bring together industry leading expertise in the global cannabis industry, including cannabis cultivation, product innovation, brand building, and distribution. Leveraging both companies' commitments to innovation and operational efficiencies, both companies will share their respective expertise and know-how to capitalize on opportunities for growth through a broadened product offering and accelerated CPG innovation. Upon closing, Tilray Brands will nominate Denise Faltischek, CSO and Head of International, to the HEXO Board of Directors, in addition to appointing one Board observer. Under the terms of the agreement, and subject to the satisfaction of specific closing conditions, Tilray Brands would acquire 100% of the remaining $193M outstanding principal balance of the Note, all of which were originally issued by HEXO to HTI. As consideration for Tilray Brands' acquisition of the Note, Tilray Brands will pay 95% of the then outstanding principal balance for the Note, plus accrued and unpaid interest thereon. Until closing, HTI may continue to redeem the Note pursuant to its terms; however, in no event shall the outstanding principal balance of the Note, when ultimately purchased by Tilray Brands, be less than $160M. Among the various agreed amendments to the Note, the initial conversion price will be C$0.85, which implies that, as of April 11, 2022, Tilray Brands has the right to convert into approximately 35% of the HEXO Shares. The Purchase Price shall be satisfied in cash, common shares of Tilray Brands, or a combination thereof, at Tilray Brands' sole discretion. HEXO will not receive any proceeds as a result of Tilray Brands' purchase of the Note from HTI. In connection with the Transaction, the parties will amend and restate the existing Note to, among other things, extend the maturity date by three years, to May 1, 2026; provide for the revised interest amounts previously identified; and amend or eliminate certain affirmative and negative covenants, including as it relates to minimum liquidity and minimum EBITDA covenants. The Note will also provide Tilray Brands with subscription rights and top-up rights in respect of all future equity and debt issuances by HEXO following closing, other than in respect of certain customary exceptions. The Transaction is subject to customary closing conditions, including completion of all required amendments to the terms of the Note; receipt of any necessary approvals from the Toronto Stock Exchange and the Nasdaq Stock Market; receipt of all consents and approvals required by any regulatory authorities; receipt of shareholder approval from the HEXO shareholders; no material adverse effect having occurred in respect of HEXO; Tilray Brands and HEXO having entered into the commercial agreements; HEXO having a cash balance as of closing of not less than $100M and HEXO using reasonable best efforts to cause a committed equity line to be made available to HEXO for up to C$180M on terms acceptable to both HEXO and Tilray Brands.

07:47 EDT Altamira Therapeutics sees 2022 cash requirements CHF 11M - CHF 13M - The Company expects its total cash requirements for FY 2022 to be in the range of CHF 11 to 13 million, for which it can draw upon its cash position as well as further issuances of common shares under its equity line with Lincoln Park Capital and its "at-the-market" program with A.G.P. Additional sources of funding may arise from the planned spin-off or divestiture of its legacy assets.

07:46 EDT Altamira Therapeutics expects top-line data from TRAVERS Phase 2 trial in Q2 - Development of Altamira's AM-125 program for the treatment of vertigo in 2021 was still impacted by COVID-19 related intermittent slowdowns in recruitment for the TRAVERS Phase 2 clinical trial. In March 2022, the Company was able to complete enrollment into Part B of the trial, which recruited 75 patients with acute vertigo following neurosurgery. Top-line data from the trial are expected for 2Q-2022. An interim analysis of Part A of the trial had demonstrated a dose-dependent improvement in balance as well as good safety and tolerability of ascending doses of AM-125. At the highest dose of 20 mg, AM-125-treated patients demonstrated, on average, a 2.6-fold improvement in Tandem Romberg test performance from baseline to six weeks, compared to those who received placebo. This positive outcome was supported by similar improvements in additional efficacy measures, including additional objective as well as clinician- and patient-reported outcomes. Altamira is currently preparing the submission of an IND to the FDA for the next steps in the clinical development of AM-125. The product is an intranasal formulation of betahistine, which has been widely used for decades in tablet form as a vestibular stimulant and standard of care in vertigo treatment and management around the world, with the US being a notable exception. Vestibular dysfunction affects more than one third of the U.S. population 40 years of age and older. Because of its ability to circumvent first-pass metabolism, AM-125 has been shown to have 5-to-29 times higher bioavailability than orally administered betahistine. Even without a US market, worldwide sales of oral betahistine are approximately $450 million. Altamira intends to pursue partnering opportunities with AM-125.

07:43 EDT Altamira Therapeutics targets FDA IND in 2023 for PoC study of AM-401 - In June 2021, Altamira entered the field of RNA therapeutics through the share-based acquisition of Trasir Therapeutics. Trasir is a pioneer in the development of nanoparticles for extrahepatic nucleic acid delivery, that is of RNA molecules to targets outside the liver. The Company's proprietary peptide-based technology platforms, OligoPhore and SemaPhore, enable the safe and effective delivery of siRNA and mRNA, respectively, into target cells using systemic or local administration. The technology has been successfully tested in numerous animal disease models, including indications in various types of cancer and inflammatory diseases. Altamira has selected KRAS-driven cancers, which may affect the pancreas, lungs or colorectum, among others, as the first indication for drug development. Under project code AM-401, the Company is aiming for an FDA IND in 2023 to initiate a clinical proof-of-concept study in humans. Since the acquisition of Trasir, Altamira has expanded its RNA activities and resources. Dr. Samuel Wickline, Trasir's founder who became the Company's Chief Scientific Officer, was recently joined in the leadership team by Dr. Covadonga Paneda, Altamira's new Chief Development Officer. The Company intends to leverage its OligoPhore / SemaPhore platform through out-licensing to other biopharmaceutical companies and has already initiated corresponding business development activities.

07:40 EDT American Airlines sees Q1 CASM up 12%-13% vs. 1Q19 - During the first quarter, the company flew 59.5 billion total available seat miles, down 10.7% versus the first quarter of 2019, American Airlines said in a regulatory filing. The company expects its first quarter CASM to be up between 12% and 13% versus the first quarter of 2019, compared to its previous guidance of up between 11% and 13%. The company expects its cost of fuel to be between $2.80 and $2.85 per gallon of jet fuel and to have consumed approximately 895 million gallons during the first quarter of 2022. The company expects to report net special items of approximately $160M in the first quarter before the effect of taxes. The company expects to end the first quarter with approximately $15.5B in total available liquidity.

07:36 EDT Clear Blue Technologies selected to provide power solutions to ViaSat - Clear Blue Technologies announced Viasat has selected Clear Blue's Nano-Grid and new Pico-Grid power products to provide reliable, low-cost, clean energy solutions and management services at Viasat's satellite-based Community Internet locations in Nigeria.

07:35 EDT Inozyme provides update for Phase 1/2 trials of INZ-701 - Inozyme Pharma announced that the first patient has been dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in the ongoing Phase 1/2 clinical trial in ENPP1 Deficiency has been fully enrolled. "With momentum in patient enrollment in the trials for our lead indications and our recently-reported positive preliminary data in ENPP1 Deficiency, we believe we are another step closer to potentially bringing a much-needed therapeutic option to patients suffering from these devastating diseases," said Axel Bolte, MSc, MBA, Inozyme's co-founder, president, and CEO. "In preclinical models of ABCC6 Deficiency and ENPP1 Deficiency, INZ-701 increased plasma pyrophosphate levels and prevented soft tissue calcification, a key manifestation of both conditions. We expect to report preliminary biomarker and safety data from our ABCC6 Deficiency trial in the second quarter of 2022 and topline data from the ENPP1 Deficiency trial in the second half of 2022." The Company recently reported positive preliminary biomarker, safety, and pharmacokinetic data from the first three patients treated in the Phase 1 portion of its ongoing first-in-human Phase 1/2 clinical trial of INZ-701 in adult patients with ENPP1 Deficiency. At the 0.2 mg/kg dose level of INZ-701, all three patients showed rapid, significant, and sustained increases in PPi levels.

07:34 EDT MIND Technology announces recent orders totaling $7.3M - MIND Technology announced that in recent weeks it has received orders totaling approximately $7.3M, and these orders are expected to be delivered later in this fiscal year. These orders stem from its Seamap and Klein Marine Systems units which have piqued interest in recent months as both the energy industry's pricing environment has improved and the geopolitical and security situation around the world continues to evolve. The company's Seamap unit received an order totaling approximately $4.8M from HJ Shipbuilding & Construction to provide its GunLink 4000 source controller system, BuoyLink 4DX GNSS positioning system, air gun arrays and tail buoys for a new build seismic research vessel. The multi-streamer, multi-purpose vessel is being built for the Korean Institute of Geoscience and Mineral Resources. MIND's Klein Marine Systems unit has also recently seen increased interest in multi-beam sonar systems, specifically the Klein 5000 and Klein 5900 systems, which has resulted in orders totaling approximately $2.5M. These systems provide high-resolution images and allow for acquisition of data at high survey speeds. Thus, these are well suited for mine counter measure missions and fill critical needs for the United States and its allies. Furthermore, the company has responded to requests for quotes for additional systems, totaling approximately $3.5M. In some cases, the orders include integrated launch and recovery systems.

07:33 EDT Lilium submits full set of Means of Compliance proposals to EASA for Lilium Jet - Lilium announced that it has submitted a full set of Means of Compliance proposals to the European Union Aviation Safety Agency for the type certification of the Lilium Jet. The submission to EASA represents a milestone on the path to certifying Lilium's revolutionary eVTOL aircraft, the Lilium Jet. The Means of Compliance are an essential part of the program by which an aircraft manufacturer demonstrates a new aircraft type conforms with airworthiness requirements prescribed in the certification basis previously identified by EASA. EASA's type certification process consists of the following main steps: Technical Familiarization and Certification Basis; Establishment of the Certification Program; Compliance demonstration. Lilium completed the first step and received its EASA certification basis in 2020. As part of the second step, EASA and Lilium are required to define and agree on the means to demonstrate compliance of the aircraft type with each requirement of the certification basis. Submitting Means of Compliance proposals to EASA represents an important milestone towards completion of that second step and moves Lilium closer to type certification of the Lilium Jet. Lilium is pursuing type certification for the Lilium Jet with EASA and concurrent type certification validation with the U.S. Federal Aviation Administration, the FAA, under the provisions of the Bilateral Aviation Safety Agreement between the EU and U.S.

07:32 EDT XL Fleet announces Donald Klein as CFO effective April 11 - XL Fleet Corp announced that Donald P. Klein has been appointed Chief Financial Officer of XL Fleet, effective April 11. Mr. Klein is a seasoned finance executive with extensive accounting, analysis, and public reporting experience. He is an influential leader and trusted business partner with a strong track-record of accomplishments, focus and business acumen. Mr. Klein replaces Chris Goldner, who was appointed as the Company's interim Chief Financial Officer in February .

07:32 EDT Achilles Therapeutics announces manufacturing expansion in UK, US - Achilles Therapeutics announced clinical manufacturing expansion in the United Kingdom and the United States. Achilles' manufacturing facility at the Cell & Gene Therapy Catapult in Stevenage, UK, has received a manufacturing license from the UK Medicines and Healthcare products Regulatory Agency, MHRA, and, separately, the Company has entered into a partnership agreement for clinical manufacturing with the Center for Breakthrough Medicines, CBM, a contract development and manufacturing organization in King of Prussia, Pennsylvania. The additional peak annual capacity of up to 600 doses of the Company's personalized clonal neoantigen-reactive T cell product candidates, known as cNeT, will support clinical manufacturing in the two ongoing Phase I/IIa CHIRON and THETIS clinical trials in advanced non-small cell lung cancer and recurrent or metastatic melanoma, respectively. Following the receipt of a manufacturing license from the MHRA, the Catapult facility is now GMP certified to produce clinical grade doses of cNeT. This second GMP manufacturing site at the Catapult will initially support Achilles' proprietary VELOS manufacturing process with an annual capacity of 200 cNeT doses at peak production.

07:17 EDT BioCardia receives FDA approval for IND application for BCDA-04 - BioCardia announced that the U.S. Food and Drug Administration has approved the Company's Investigational New Drug application for BCDA-04, a proprietary allogeneic mesenchymal cell population that is Neurokinin-1 receptor positive. This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome due to COVID-19, with trial initiation expected in the third quarter of 2022. The first part of the clinical trial will evaluate increasing doses of the NK1R+ MSCs and the optimal dose will be taken to Phase II in a randomized study in adult patients recovering from ARDS due to COVID-19.

07:14 EDT Silver Tiger Metals announces drill results from El Tigre Vein - Silver Tiger Metals has intersected 1,380.9 g/t AgEq over 0.5 meters within a broader interval of 23.8 meters grading 113.3 g/t AgEq in the El Tigre Vein. Highlights from initial 7 drill holes down dip under the El Tigre historic workings at the North end include the following: Hole ET-21-295: 0.5 meters grading 1,380.9 g/t silver equivalent from 102.0 meters to 102.5 meters, consisting of 1,200.0 g/t silver, 2.12 g/t gold, 0.16% copper, 0.20% lead and 0.05% zinc within 23.8 meters grading 113.3 g/t silver equivalent from 80.0 meters to 103.8 meters, consisting of 94.7 g/t silver, 0.19 g/t gold, 0.02% copper, 0.06% lead and 0.03% zinc. Hole ET-21-285: 1.5 meters grading 844.5 g/t silver equivalent from 300.2 meters to 301.7 meters, consisting of 23.5 g/t silver, 10.70 g/t gold, 0.06% copper, 0.24% lead and 0.21% zinc within 10.2 meters grading 135.9 g/t silver equivalent from 298.7 meters to 308.9 meters, consisting of 6.5 g/t silver, 1.63 g/t gold, 0.01% copper, 0.07% lead and 0.12% zinc. Silver Tiger's CEO, Glenn Jessome, stated, "The first down dip holes on the El Tigre Vein at the historic mine are delivering high grade silver intercepts within a broad mineralized zone. These first holes are shallow as the mining on the northern end of the El Tigre Vein stopped at level 4 at about 80 meters from surface. Deeper holes are currently being drilled down dip on the El Tigre Vein at the North end of the historic mine." As press released on February 22, 2022 Silver Tiger contracted Cominvi, a Mexican underground contract mining and development company to rehabilitate the Historic El Tigre Mine. Cominvi began underground rehabilitation March 21, 2022. Cominvi are progressing very quickly in the underground rehabilitation of the Historic El Tigre Mine and have already completed over 215 meters of rehabilitation in Level 7, which was the main portal to the mine. Glenn Jessome further stated, "We are extremely satisfied with the first several weeks of Cominvi's underground rehabilitation of the old mine. Their expertise, professionalism and safety profile is exceptional. The first 215 meters of rehabilitation has gone quickly and smoothly which is a testimony to the structural integrity of the workings thus far. We expect to reach the Sooy Vein workings in another 255 meters, which is approximately 470 meters from the Level 7 portal."

07:10 EDT Schrodinger updates Wee1 inhibitor program with new data at AACR - Schrodinger presented new preclinical data from its Wee1 inhibitor program in a poster session at the American Association of Cancer Research, AACR, Annual Meeting taking place in New Orleans. Schrodinger has identified multiple, highly selective and structurally distinct Wee1 inhibitors with optimized physicochemical properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models. The data presented show that Schrodinger's Wee1 inhibitors have therapeutic potential for use as monotherapy and as part of combination therapy with other agents. "The strength of our data underscore the potential of our novel, orally available and potent Wee1 inhibitors and provide an opportunity to advance a potential best-in-class Wee1 inhibitor into the clinic," said Karen Akinsanya, Ph.D., president of R&D, therapeutics, at Schrodinger. "The differentiated and balanced profile of our Wee1 molecules highlights the impact of our computational platform when deployed at scale to overcome design challenges, such as selectivity and ADME optimization. Our unique lead series were identified by assessing more than 445M potential compounds computationally with only 42 that were synthesized for further analysis."

07:06 EDT VistaGen, AffaMed complete regulatory preparations for PALISADE study - VistaGen Therapeutics and AffaMed Therapeutics announced they have completed regulatory preparations to initiate PALISADE Global, a Phase 3 clinical trial to evaluate the efficacy, safety, and tolerability of VistaGen's PH94B for the acute treatment of anxiety in adults with social anxiety disorder, or SAD, in the U.S. and China. The primary purpose of PALISADE Global, the design of which is based on VistaGen's ongoing PALISADE-1 and PALISADE-2 Phase 3 clinical studies of PH94B in the U.S., is to support potential commercialization of PH94B in China and other markets outside of the U.S.

07:05 EDT AerCap reports Q1 major business transactions - AerCap Holdings has announced its major business transactions during the Q1: Signed 102 lease agreements, including 14 widebody aircraft, 62 narrowbody aircraft, 2 regional jets, 8 engines and 16 helicopters; Completed 25 purchases for 23 aircraft, including 15 Airbus A320neo Family aircraft, 1 Airbus A220 aircraft and 4 Boeing 737 MAX aircraft for AerCap's owned aircraft portfolio and 3 aircraft for AerCap's managed aircraft portfolio, and 2 engines; Executed 30 sale transactions for 26 aircraft, including 2 Airbus A320 Family aircraft, 3 Airbus A320neo Family aircraft, 2 Airbus A330s, 3 Boeing 737NGs, 1 Boeing 767-300ER, 2 Boeing 777-200ERs, 1 Boeing 737-300SF, 5 Embraer E190 E2s and 1 Embraer E190 from AerCap's owned aircraft portfolio and 6 aircraft from AerCap's managed aircraft portfolio, 2 engines and 2 helicopters; and signed financing transactions for approximately $2.1B.

07:04 EDT GoldMining begins exploration drilling on La Mina project in Colombia - GoldMining is pleased to announce that it has commenced a program of exploration drilling on the La Garrucha target, located less than one kilometre to the east and immediately adjacent to the existing mineral resources on the company's 100% owned La Mina project, located in Antioquia, Colombia. Alastair Still, CEO of GoldMining, commented, "The start of our first drilling campaign on the La Garrucha target at La Mina marks an important milestone for our company as we begin to unlock value from our portfolio of gold and gold-copper projects located throughout the Americas. This exploration drilling program is designed to test an exciting target, which we believe has the potential to expand upon the project's existing resource base and represents an opportunity to enhance the economics of the recently announced Preliminary Economic Assessment. We are planning approximately 3,600 metres of drilling in 6 holes with the core to be logged and sampled at our existing La Mina project facilities. Samples of sawn core will be transported to ALS Colombia LTDA in Medellin for assaying."

07:04 EDT Takeda Pharmaceutical announces SHP643-301 study meets objectives - Takeda announced that the Phase 3 SHP643-301 study evaluating the safety profile and pharmacokinetics, or PK, of Takhzyro in patients two to less than 12 years of age is complete and has met its objectives. The safety profile was consistent with that seen in the clinical program for patients 12 years of age and older; there were no serious adverse events and no dropouts due to adverse events. The study also successfully reached the secondary objective evaluating the clinical activity/outcome of Takhzyro in preventing hereditary angioedema attacks as well as characterizing the pharmacodynamics of Takhzyro in pediatric subjects two to less than 12 years of age.

07:03 EDT ALX Oncology appoints Canamasas to board of directors - ALX Oncology (ALXO) announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors effective April 11, 2022. Dr. Canamasas currently serves as the Head of Oncology Europe, Middle East and Africa at Bayer AG (BAYRY).

07:03 EDT iHeartMedia D.C., Washington Commanders announce three-year audio partnership - The Washington Commanders announced a new three-year partnership deal with iHeartMedia D.C. to be the team's exclusive radio broadcast partner. Beginning in the 2022 season, live gameday broadcasts will run on iHeartMedia's BIG 100.3 FM and be featured on the station's website and on the iHeartRadio app, iHeartMedia's free all-in-one digital music, podcasting and live streaming radio service. This new partnership will expand the team's reach across the DMV, giving more fans the ability to listen and engage with the Washington Commanders on a daily basis and helping to grow the team's fanbase in the region. In addition to the team's radio gameday broadcast, this partnership will offer a robust lineup of exclusive programming across iHeartMedia D.C.'s radio stations and on the iHeartRadio App. New this season, fans will also be able to access archived radio broadcasts of the team's games anytime via the Commanders channel on the iHeartRadio App.

07:02 EDT Cyclacel Pharmaceuticals announces publication on fadraciclib - Cyclacel Pharmaceuticals announced a publication in the journal Leukemia titled "Cyclin-dependent kinase inhibitor fadraciclib depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells". Fadraciclib is Cyclacel's novel CDK2/9 inhibitor, currently in two Phase 1/2 trials, one for the treatment of advanced solid tumors and lymphomas and another for hematological malignancies, including patients with leukemia being treated in combination with venetoclax. "Results from this research provide further mechanistic evidence in support of our ongoing Phase 1/2 clinical study of oral fadraciclib in select hematological malignancies," said Mark Kirschbaum, M.D., Senior Vice President and Chief Medical Officer of Cyclacel. "The findings confirmed that fadraciclib suppresses MCL1 and synergizes with venetoclax, the only FDA-approved apoptosis enabling leukemia treatment. We have included a cohort within the proof-of-concept part of our Phase 1/2 study that will evaluate the combination of fadraciclib plus venetoclax in patients who have previously failed venetoclax-based regimens." Results from the study confirmed that fadraciclib inhibited CDK9 mediated transcription, reduced levels of the short-lived anti-apoptotic protein MCL1, and induced apoptosis in primary CLL cells. The data highlighted the importance of continuous treatment to prevent recovery of MCL1 protein levels. Fadraciclib was shown to combine synergistically with venetoclax. Furthermore, it was demonstrated that the best synergy, with fadraciclib and venetoclax given at the same time, was achieved in 17p deleted CLL cells, which were not sensitive to either agent alone. Fadraciclib also overcame protection mediated by stroma CLL cells and lymph node microenvironment. The data support the rationale for pursuing clinical development of fadraciclib, either alone or in combination with a BCL2 antagonist, for the treatment of CLL.

07:02 EDT Actinium and Immedica sign agreement for Iomab-B - Actinium Pharmaceuticals and Immedica Pharma announced entering a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant, or BMT, and other cell and gene therapies. A pivotal Phase 3 trial, Study of Iomab-B versus Conventional Care in Elderly, Relapsed or Refractory Acute Myeloid Leukemia, or SIERRA, of Iomab-B completed patient enrollment in the third quarter of 2021 with topline data expected in the third quarter of 2022. BMT is the only potentially curative treatment option for patients with active, relapsed or refractory acute myeloid leukemia, or AML.

06:57 EDT Blue Apron names Josh Friedman as Chief Product Officer - Blue Apron announced that Josh Friedman has been named Chief Product Officer, effective April 18. Friedman brings multi-decade, extensive experience in strategic, digital and product leadership roles to Blue Apron. As Chief Product Officer, he will be responsible for Blue Apron's product strategy, overseeing cross-functional efforts between fulfillment, culinary and digital product. Chief Product Officer is a recent addition to Blue Apron's Executive Leadership Team. Friedman will be reporting to President and CEO Linda Findley. Most recently, Friedman was the Head of Digital Products at The Neiman Marcus Group.

06:52 EDT CarMax sees FY23 CapEx $500M - The company said, "We currently plan to open ten stores in fiscal 2023, including our expected entry into the New York metro market. We estimate capital expenditures will increase to approximately $500 million in fiscal 2023 from $308.5 million in fiscal 2022. The increase in planned capital spending in fiscal 2023 largely reflects spending to support our future long-term growth, including investments in auction, sales, and production facilities, and technology."

06:47 EDT International Game subsidiary signs supply contract with ALC - International Game announced that its subsidiary, IGT Canada Solutions, has signed a contract with the Atlantic Lottery Corporation, or ALC, to provide 1,375 CrystalDual 27 video lottery terminals, or VLTs, throughout the remainder of the year.

06:37 EDT New Gold reports Q1 gold equivalent production 87,696 ounces - Reports Q1 gold production 68,101 ounces. Reports Q1 copper production 8.2M pounds. New Gold reported first quarter operational results for the company as of March 31. The Company is also providing notice that it will be releasing its Q1 financial results before markets open on Monday, May 2. "The first quarter saw both of our operations deliver total gold equivalent production of 87,696 ounces as we begin a year focused on operational excellence and optimization at both assets," stated Renaud Adams, president and CEO. "At Rainy River, we achieved quarter over quarter production growth despite lower tonnes mined as a result of an increase in COVID-19 cases at site in the first part of the quarter, which impacted equipment utilization, and the cold weather affecting drilling productivity. The milling rate was also impacted during the quarter due to mechanical maintenance on the SAG mill and crusher, and weather conditions impacting stockpile movement. At New Afton, the planned closure of the Lift 1 cave was completed with the exception of the recovery level, commissioning of the thickened and amended tailings facility was completed, and we continued to advance the B3 ramp-up and C-Zone development. Lastly, we released an updated Rainy River technical report where Rainy River's mine life has extended to 2031 with the conversion of an additional 569,000 gold ounces in the underground main zones."

06:35 EDT Air Lease announces Q1 activity update - Air Lease (AL) announced an update on aircraft investments, sales, new significant financing, and other activity occurring in the first quarter of 2022. As of March 31, ALC's fleet was comprised of 391 owned aircraft and 93 managed aircraft, with 451 new aircraft on order from Boeing (BA) and Airbus (EADSY) set to deliver through 2028. Aircraft Investments: Delivered eight new aircraft from ALC's order book including one Airbus A320neo, two Airbus A321neos, one Airbus A330-900neo, three Boeing 737-8s, and one Boeing 737-9; Purchased one incremental Boeing 737-800, which was concurrently leased to an ALC customer; Aircraft investments in the quarter totaled approximately $490M. Sales: No aircraft sales occurred during the quarter. Financing: Issued $1.5B of senior unsecured medium-term notes comprised of $750M of 2.20% senior unsecured medium-term notes due 2027, and $750M of 2.875% senior unsecured medium-term notes due 2032. Russia Exposure: "In March of 2022, we terminated leases for all ALC aircraft on lease to Russian airline customers. We currently have 21 owned aircraft remaining in Russia, representing approximately 3.4% of our fleet by net book value as of March 31, 2022."

06:10 EDT Organigram says it is better equipped to fulfill demand in FY22 - The company said, "the continuation of shipments to Canndoc in Israel and Cannatrek in Australia is expected to generate higher sequential revenue in FY22 as compared to FY21. The Company believes it is better equipped to fulfill demand in FY22 with larger harvests expected compared to FY21. Revenues in FY22 to date included two shipments to Canndoc that totaled approximately $7.0M, and one shipment to Cannatrek for approximately $1.0M. Orders received from other international customers support the Company's expectation of continued revenue growth from FY21 to FY22. Organigram expects to be positioned to generate further revenue growth from the production of soft chews/gummies and other edible products. The Company also expects to realize additional revenue through the recent acquisition of Laurentian and will make growth-focused capital expenditures at Laurentian which have the potential to further increase EBITDA generation. Since the acquisition, the Company has accelerated the distribution and sale of Tremblant Cannabis, its flagship hash brand in Ontario, increasing distribution from 25% to 40% of retail stores and growing quarterly sales by 21% compared to Laurentian's sales in the three months ended November 30. By leveraging Organigram's industry-leading national distribution and field sales network, Laurentian products will be available in all Canadian provinces in FY22."

06:09 EDT Organigram expects Q3 revenue to be higher than Q2 - The company said, "Organigram currently expects Q3 revenue to be higher than Q2. This expectation is largely due to ongoing sales momentum, stronger forecasted market growth, the Company's expanded product line in multiple segments, greater capacity to meet demand at the Moncton Campus, increased throughput at the Winnipeg facility and the Laurentian acquisition. Net revenue growth is expected from the Company's products as evidenced by Organigram's growing national adult-use recreational retail market share from 7.6% in Q1 of September 2021 to 8.4% in March 2022."

06:06 EDT KBR announces settlement agreement with JKC, power plant subcontractor - KBR (KBR) announced that JKC Australia LNG joint venture, in which KBR has a 30% ownership interest, and Kellogg Brown & Root Pty Ltd entered into a conditional settlement agreement to resolve outstanding claims and disputes between JKC and its power plant subcontractor, the consortium comprising: the unincorporated joint venture between CH2M Hill Australia Pty Limited and UGL Infrastructure Pty Limited, General Electric (GE) and General Electric International. As a result of the settlement agreement, KBR expects to receive approximately $271M of cash in two payments: $203M in April and $68M in March 2023, at prevailing exchange rates. KBR expects to report a non-cash loss of approximately $140M in its Q1 results for the period ended March 31. The settlement agreement remains conditional and the outstanding arbitration between JKC and the consortium is proceeding until the conditions are satisfied. If any member of the consortium fails to take the actions necessary to satisfy the conditions to the settlement agreement, the settlement agreement will become void. Should the conditions of the settlement agreement be satisfied, the parties agree to withdraw all claims and terminate the ongoing arbitration between the parties.

05:17 EDT Myovant Sciences, Pfizer announce deficiencies found by FDA in Myfembree sNDA - Myovant Sciences (MYOV) and Pfizer (PFE) announced an update on the supplemental new drug application, or sNDA, for Myfembree for the management of moderate to severe pain associated with endometriosis. In accordance with the ongoing review of the application, on April 6, the FDA provided notice to the companies that the agency identified deficiencies that preclude discussion of labeling and/or post-marketing requirements and commitments at this time. The FDA did not provide additional detail. The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review. Myovant and Pfizer will continue to work with the FDA to determine next steps with the application.

05:14 EDT PureTech Health publishes preclinical proof-of-concept Glyph platform data - PureTech Health announced the publication of preclinical proof-of-concept demonstrating that PureTech's Glyph platform can enhance the oral bioavailability of buprenorphine, or BUP, a clinically-validated opioid replacement therapy, further expanding the range of clinically-validated drug classes shown to be amenable to the Glyph technology. The paper, published in Frontiers in Pharmacology, applies the Glyph technology to BUP, a potent analgesic that is widely used for severe pain management and opioid replacement therapy but is not currently available in an ingestible oral dosage form due to poor oral bioavailability. In preclinical models, the researchers observed increases in bioavailability of up to 20-fold and statistically significant increases in lymphatic transport.

05:09 EDT Autoliv launches multi-year commitment to support UNRSF - Autoliv is supporting the United Nations Road Safety Fund, or UNRSF, in an effort to strengthen insights into road safety challenges, contribute to safer mobility and help deliver Autoliv's goal of saving 100,000 lives a year. By exchanging insights, knowledge, and data, Autoliv and UNRSF will actively support the Global Plan for the Second Decade of Action 2021-2030, which seeks to prevent at least 50% of road traffic deaths and injuries by 2030.

05:04 EDT WWE announces first UK event in 30 years to be held in Wales - WWE announced that the first major WWE stadium event to be held in the United Kingdom in more than 30 years will emanate from Principality Stadium in Cardiff, Wales, on Saturday, September 3.